Chimeric antigen receptor comprising CD30-derived intracellular signalling domain, immune cell expressing the same, and use thereof
The CD30-derived intracellular signaling domain enhances CAR-T cell proliferation and survival, addressing the limitations of existing CAR-T cell therapies by improving antitumor efficacy and cytokine secretion against solid tumors.
Patent Information
- Application Number
- KR1020230041676
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-30
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2043-03-30
AI Technical Summary
Existing CAR-T cell therapies are ineffective against solid tumors due to limited persistence, difficulty in reaching solid tumors, and the immunosuppressive tumor microenvironment, necessitating a strategy to enhance proliferation and survival of CAR-T cells.
A chimeric antigen receptor comprising a target antigen binding domain, a transmembrane domain, and an intracellular signaling domain derived from CD30, specifically utilizing the TRAF binding site sequences of CD30 to enhance proliferation and survival of immune effector cells, particularly CAR-T cells.
The CD30-derived intracellular signaling domain increases antitumor efficacy and cytokine secretion ability, improving the therapeutic effect against both hematological and solid tumors.
Smart Images

Figure 112023035794052-PAT00005_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a chimeric antigen receptor comprising an intracellular signaling domain derived from CD30, an immune cell expressing the same, and uses thereof. Background Technology
[0002] Over the past few decades, surgical procedures, radiation therapy, and chemotherapy have been developed as methods to treat cancer, but limitations such as serious side effects and resistance caused by mutations have emerged. Recently, immune checkpoint inhibitors and adoptive immune cell therapy have been gaining attention as promising cancer treatments.
[0003] Chimeric antigen receptor (CAR)-T cell therapy is a treatment method that involves extracting cytotoxic T cells from the body, genetically modifying them to express a CAR capable of recognizing a specific antigen, and then reintroducing them. Through this process, the cells can selectively kill cancer cells by recognizing antigens expressed by the cancer cells on the major histocompatibility complex (MHC) without restriction. A CAR consists of a single-chain variable fragment (scFv) capable of recognizing a specific antigen, a spacer domain, a transmembrane domain, and an intracellular signaling domain that transmits activation signals for T cells.
[0004] First-generation CARs consist of an antigen-recognizing scFv and a single intracellular signaling domain; the signaling domain utilized CD3 zeta, the major T cell receptor (TCR) signaling chain, or FcR-gamma, the signaling chain of the activating Fc receptor. However, first-generation CAR-T cells lacked clinical efficacy due to limited proliferation and viability in vivo. To overcome this, second-generation CARs were developed by adding signaling sites of costimulatory receptors—such as CD28, 4-1BB, ICOS, OX40, and CD27—to CD3 zeta, followed by third-generation CARs that combined two different types of costimulatory domains. Both second and third-generation CARs demonstrated enhanced anticancer effects through active proliferation and long-term viability in vivo. In addition, to further enhance the effect against solid tumors, research continues on 4th generation CARs that co-express cytokines or co-stimulatory ligands that help activate T cells based on 2nd or 3rd generation CARs, and 5th generation CARs that include technology to inhibit human leukocyte antigen (HLA) or TCR genes.
[0005] To enhance the efficacy of CAR-T cells, research is being conducted to optimize the domains constituting the CAR; in particular, co-stimulatory domains are known to play a crucial role in the proliferation, expansion, maintenance, anti-tumor activity, and cytokine secretion of CAR-T cells. Commonly used co-stimulatory domains are broadly classified into the Immunoglobulin (Ig) superfamily, such as CD28 and ICOS (CD278), and the Tumor Necrosis Factor Receptor (TNFR) superfamily, which includes 4-1BB (CD137), OX40 (CD134), and CD27. Ig superfamily co-stimulatory domains activate phosphatidylinositol 3-kinase (PI3K), thereby activating the protein kinase B (Akt) and nuclear factor κB (NF-κB) signaling pathways. On the other hand, TNFR superfamily co-stimulatory domains activate the NF-κB signaling pathway through various types of TNF receptor-associated factors (TRAFs).
[0006] As a conventional CAR-T cell therapy, human CD19-targeted CAR-T cell therapies have shown impressive therapeutic effects on blood cancers such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and non-hodgkin's lymphoma, but have been ineffective against solid tumors. This is because CAR-T cells lack persistence in the body, are difficult to reach (trafficking) to solid tumors, and solid tumors are surrounded by an immunosuppressive tumor microenvironment.
[0007] Therefore, a strategy is needed to increase the proliferation and survival of CAR-T cells in vivo for excellent therapeutic effects even against solid tumors. Prior art literature
[0008] 1. Michel Sadelain et al, 2013, Cancer Discov 3(4):388-98.2. Cheng Zhang et al, 2017, Biomark Res 5:223. Barbara Savoldo et al, 2011, J Clin Invest 121(5):1822-64. Claudia M Kowolik et al, 2006, Cancer Res 15;66(22):10995-10045. Adrienne H Long et al, 2015, Nat Med 21(6):581-906. Michael C Milone et al, 2009, Mol Ther 17(8):1453-647. Sonia Guedan et al, 2014, Blood 14;124(7):1070-808. Andreas A Hombach et al, 2012, Oncoimmunology 1;1(4):458-4669. De-Gang Song, 2012, Blood 19;119(3):696-70610. Lijun Zhao et al, 2019, Front Immunol 10: 225011. Renier J Brentjen et al, 2013, Sci Transl Med 20;5(177):177ra3812. David L Porter et al, 2015, Sci Transl Me 2;7(303):303ra13913. Stephan A Grupp et al, 2013, N Engl J Med 18;368(16):1509-151814. Jonathan H Esensten, 2016, Immunity 17;44(5):973-8815. Robert Weinkove, 2019, Clin Transl Immunology 11;8(5):e1049 The problem to be solved
[0009] The object of the present invention is to provide a chimeric antigen receptor capable of enhancing antitumor efficacy and cytokine secretion ability, and uses thereof. means of solving the problem
[0010] To achieve the above objective, the present invention provides a chimeric antigen receptor comprising: a target antigen binding domain; a transmembrane domain; an intracellular signaling domain derived from C30 comprising one or more amino acid sequences selected from the group consisting of SEQ ID NO: 44, 46, 48 and 50; and a CD3ζ intracellular signaling domain.
[0011] The present invention also provides a nucleic acid molecule encoding the chimeric antigen receptor.
[0012] The present invention also provides a vector comprising the nucleic acid molecule.
[0013] The present invention also provides an isolated immune effector cell comprising the chimeric antigen receptor, a nucleic acid molecule encoding the same, or a vector comprising the nucleic acid molecule.
[0014] The present invention also provides an antitumor composition comprising the immune effector cells.
[0015] The present invention also provides a method for treating cancer comprising the step of administering a therapeutically effective amount of immune effector cells to a subject in need thereof. Effects of the invention
[0016] The present invention has the effect of enhancing antitumor efficacy and cytokine secretion ability by using a chimeric antigen receptor comprising a portion of the sequence of the TRAF binding site of the CD30 domain as an intracellular signaling domain, thereby increasing the proliferation and survival of immune effector cells. Brief explanation of the drawing
[0017] FIG. 1a shows CD19-28-z, CD19-30L-z, CD19-30M-z, and CD19-30M according to an embodiment of the present invention. mut -z, CD19-30ΔM-z, CD19-30S-z CAR structure schematic diagrams are shown. FIG. 1b shows human blood cancer cell line U937 through flow cytometry analysis according to an embodiment of the present invention mock , U937 CD19 The expression levels of human CD19 antigen (red area) in IM-9 and Raji are shown based on isotype (gray area). FIG. 1c shows CD19-28-z, CD19-30L-z, CD19-30M-z, and CD19-30M through flow cytometry analysis according to an embodiment of the present invention. mut The expression levels of each CAR (red area) in KHYG-1, NK-92, alpha-beta T, and gamma-delta T cells into which -z, CD19-30ΔM-z, and CD19-30S-z CARs were introduced are shown relative to the group without CAR introduction (NT, blue area). FIG. 1d shows CD19-28-z, CD19-30L-z, CD19-30M-z, and CD19-30M according to an embodiment of the present invention. mut It shows the cytotoxic activity at various E / T ratios against CD19-positive and negative human blood cancer cell lines in KHYG-1, NK-92, alpha-beta T, and gamma-delta T cells introduced with CD19-z, CD19-30ΔM-z, and CD19-30S-z CARs. FIG. 2a shows CD19-30S-z, CD19-30ΔS-z, and CD19-30ΔS according to an embodiment of the present invention. YN -z, CD19-30ΔS YF -z Shows a schematic diagram of the CAR structure. Figure 2b shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which CD19-28-z, CD19-30L-z, CD19-30S-z, and CD19-30ΔS-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 2c shows the cytotoxic activity at various E / T ratios against each CD19-positive and negative human blood cancer cell line in alpha-beta T and gamma-delta T cells into which CD19-28-z, CD19-30L-z, CD19-30S-z, and CD19-30ΔS-z CARs according to an embodiment of the present invention have been introduced. FIG. 2d shows CD19-28-z, CD19-30S-z, and CD19-30ΔS through flow cytometry analysis according to an embodiment of the present invention YN -z, CD19-30Δ YF The expression levels of each CAR in alpha-beta T and gamma-delta T cells to which -z CAR was introduced (red area) are shown relative to the group not to which CAR was introduced (NT, blue area). FIG. 2e shows CD19-28-z, CD19-30S-z, and CD19-30ΔS according to an embodiment of the present invention YN -z, CD19-30ΔS YF -z CAR-introduced alpha-beta T and gamma-delta T cells demonstrate cytotoxic activity at various E / T ratios against CD19-positive and negative human blood cancer cell lines, respectively. FIG. 3a shows a schematic diagram of CD19-28-z, CD19-ICOS-z, CD19-4-1BB-z, CD19-OX40-z, CD19-27-z, and CD19-30S-z CAR structures according to an embodiment of the present invention. Figure 3b shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which CD19-28-z, CD19-ICOS-z, CD19-4-1BB-z, CD19-OX40-z, CD19-27-z, and CD19-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 3c shows the cytotoxic activity at various E / T ratios against each CD19-positive and negative human cancer cell line in alpha-beta T and gamma-delta T cells into which Ig receptor family CD19-28-z and CD19-ICOS-z CARs according to an embodiment of the present invention have been introduced, along with the cytotoxic activity in alpha-beta T and gamma-delta T cells into which CD19-30S-z CARs have been introduced. FIG. 3d shows the cytotoxic activity at various E / T ratios against each CD19-positive and negative human cancer cell line in alpha-beta T and gamma-delta T cells into which TNFR family CD19-4-1BB-z, CD19-OX40-z, and CD19-27-z CARs according to an embodiment of the present invention have been introduced, along with the cytotoxic activity in alpha-beta T and gamma-delta T cells into which CD19-30S-z CARs have been introduced. FIG. 3e shows CD19-negative U937 in alpha-beta T cells and gamma-delta T cells introduced with CD19-28-z, CD19-4-1BB-z, and CD19-30S-z CARs according to an embodiment of the present invention. mock and positive U937 CD19 It represents the secretion amounts of cytokines INF-γ, TNF-α, granzyme A, granzyme B, and perforin at an E / T ratio of 1. FIG. 4a shows a schematic diagram of CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z, and CD19-30S-27-z CAR structures according to an embodiment of the present invention. Figure 4b shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z, and CD19-30S-27-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 4c shows the cytotoxic activity at various E / T ratios against each CD19-positive and negative human blood cancer cell line in alpha-beta T and gamma-delta T cells into which CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z, and CD19-30S-27-z CARs according to an embodiment of the present invention have been introduced. FIG. 4d shows CD19-negative U937 in alpha-beta T cells and gamma-delta T cells introduced with CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-ICOS-z, CD19-30S-OX40-z, and CD19-30S-27-z CARs according to an embodiment of the present invention mock and positive U937 CD19 This represents the secretion amounts of cytokines INF-γ, TNF-α, granzyme A, granzyme B, and perforin at an E / T ratio of 1. FIG. 5a shows a schematic diagram of the BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z CAR structures according to an embodiment of the present invention. Figure 5b shows the expression levels of human BCMA antigen (red area) in human blood cancer cell lines U937, IM-9, and Daudi based on isotype (gray area) through flow cytometry analysis according to an embodiment of the present invention. Figure 5c shows the expression levels (red area) of each CAR in gamma delta T cells into which BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 5d shows the cytotoxic activity at various E / T ratios against each BCMA-positive and negative human cancer cell line in gamma delta T cells to which BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z CARs according to an embodiment of the present invention have been introduced. FIG. 6a shows a schematic diagram of the EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z, and EpCAM-28TM CAR structures according to an embodiment of the present invention. Figure 6b shows the expression levels of human EpCAM antigen (red area) in human lung cancer cell lines A549, Calu-1, NCI-H292, and NCI-H460 based on isotype (gray area) through flow cytometry according to an embodiment of the present invention. Figure 6c shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z, and EpCAM-28TM CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 6d shows the cytotoxic activity at various E / T ratios against each EpCAM-positive human lung cancer cell line in alpha-beta T and gamma-delta T cells to which EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z, and EpCAM-28TM CAR according to an embodiment of the present invention have been introduced. FIG. 6e shows a schematic diagram of the EpCAM-28-BB-z, EpCAM-30S-BB-z, and EpCAM-28-30S-z CAR structures according to an embodiment of the present invention. Figure 6f shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which EpCAM-28-BB-z, EpCAM-30S-BB-z, and EpCAM-28-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). Figure 6g shows the cytotoxic activity at various E / T ratios against each EpCAM-positive human lung cancer cell line in alpha-beta T and gamma-delta T cells into which EpCAM-28-BB-z, EpCAM-30S-BB-z, and EpCAM-28-30S-z CARs according to an embodiment of the present invention have been introduced. FIG. 7a shows a schematic diagram of the MSLN-28-z, MSLN-4-1BB-z, and MSLN-30S-z CAR structures according to an embodiment of the present invention. Figure 7b shows the expression levels of human MSLN antigen (red area) in human lung cancer cell lines NCI-H292, A549, human pancreatic cancer cell line AsPC-1, and human ovarian cancer cell line SKOV3 based on isotype (gray area) through flow cytometry according to an embodiment of the present invention. Figure 7c shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which MSLN-28-z, MSLN-4-1BB-z, and MSLN-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 7d shows the cytotoxic activity at various E / T ratios against each MSLN-positive and negative human cancer cell line in alpha-beta T and gamma-delta T cells into which MSLN-28-z, MSLN-4-1BB-z, and MSLN-30S-z CARs according to an embodiment of the present invention have been introduced. FIG. 7e shows a schematic diagram of the MSLN-28-BB-z, MSLN-30S-BB-z, and MSLN-28-30S-z CAR structures according to an embodiment of the present invention. Figure 7f shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which MSLN-28-BB-z, MSLN-30S-BB-z, and MSLN-28-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 7g shows the cytotoxic activity at various E / T ratios against each MSLN-positive and negative human cancer cell line in alpha-beta T and gamma-delta T cells into which MSLN-28-BB-z, MSLN-30S-BB-z, and MSLN-28-30S-z CARs according to an embodiment of the present invention have been introduced. FIG. 8a shows a schematic diagram of the GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z CAR structures according to an embodiment of the present invention. Figure 8b shows the expression levels of human GPC3 antigen (red area) in human liver cancer cell line HepG2, human lung cancer cell lines NCI-H292, and A549 based on isotypes (gray area) through flow cytometry according to an embodiment of the present invention. Figure 8c shows the expression levels (red area) of each CAR in gamma delta T cells into which GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 8d shows the cytotoxic activity at various E / T ratios against each GPC3-positive and negative human cancer cell line in gamma delta T cells into which GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z CARs according to an embodiment of the present invention have been introduced. FIG. 9a shows a schematic diagram of PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM CAR structures according to an embodiment of the present invention. Figure 9b shows the expression levels of human PD-L1 antigen (red area) in human pancreatic cancer cell line AsPC-1, human lung cancer cell lines NCI-H292, Calu-1, and human head and neck cancer cell line FaDu based on isotypes (gray area) through flow cytometry according to an embodiment of the present invention. Figure 9c shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 9d shows the cytotoxic activity at various E / T ratios against each PD-L1 positive and negative human cancer cell line in alpha-beta T and gamma-delta T cells into which PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM CAR according to an embodiment of the present invention have been introduced. FIG. 9e shows a schematic diagram of PD-1-28-BB-z, PD-1-30S-BB-z, and PD-1-28-30S-z CAR structures according to an embodiment of the present invention. Figure 9f shows the expression levels (red area) of each CAR in gamma delta T cells into which PD-1-28-BB-z, PD-1-30S-BB-z, and PD-1-28-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 9g shows the cytotoxic activity at various E / T ratios against each PD-L1 positive and negative human cancer cell line in gamma delta T cells introduced with PD-1-28-BB-z, PD-1-30S-BB-z, and PD-1-28-30S-z CAR according to an embodiment of the present invention. FIG. 10a shows a schematic diagram of the NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z CAR structures according to an embodiment of the present invention. FIG. 10b shows the expression levels of human B7-H6 antigen (red area) in human blood cancer cell lines U937, Raji, K562 and human lung cancer cell line A549 based on isotypes (gray area) through flow cytometry according to an embodiment of the present invention. Figure 10c shows the expression levels (red area) of each CAR in alpha-beta T and gamma-delta T cells into which NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z CARs were introduced through flow cytometry according to an embodiment of the present invention, based on the group without CAR introduction (NT, blue area). FIG. 10d shows the cytotoxic activity at various E / T ratios against B7-H6 positive and negative human cancer cell lines in alpha-beta T and gamma-delta T cells into which NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z CARs according to an embodiment of the present invention have been introduced. Figures 11a and 11b illustrate the therapeutic antitumor results of second-generation CD19-CAR expressing T cells according to the combination of CD30S and conventional ICD (CD28, 4-1BB) in an animal model xenografted with the human leukemia cell line NALM6. Figure 11a shows tumor growth over time in the CD19-28-z, CD19-4-1BB-z, and CD19-30S-z CAR-αβ T cell treatment groups according to an embodiment of the present invention, and Figure 11b shows the mouse survival rate up to 48 days between the control group and the CD19-28-z, CD19-4-1BB-z, and CD19-30S-z CAR-αβ T cell treatment groups. Tumor growth was monitored in individual mice via in vivo bioluminescence imaging and quantified by the average intensity of bioluminescence. Specific details for implementing the invention
[0018] The configuration of the present invention will be described in detail below.
[0019] The present invention relates to a chimeric antigen receptor comprising: a target antigen binding domain; a transmembrane domain; an intracellular signaling domain derived from CD30 comprising one or more amino acid sequences selected from the group consisting of SEQ ID NO: 44, 46, 48 and 50; and a CD3ζ intracellular signaling domain.
[0020] The present invention is characterized by providing a chimeric antigen receptor comprising a portion of the sequence of the region where TRAF (TNF receptor-associated factor) binds within the CD30 domain as an intracellular signal transduction domain.
[0021] The above CD30 is a transmembrane glycoprotein receptor with a size of 120 kD, a member of the TNFR (tumor necrosis factor receptor) family, and is expressed in T cells and B cells. When CD30 is activated, it attracts TNFR-associated factors (TRAF1, 2, 5) and activates JUNB or AP-1 transcription factors via the NF-kB or MAPK signaling pathways. This not only increases the proliferation and survival of T cells but also causes their phenotype to differentiate into a memory form. Therefore, the inventors intend to increase the proliferation and survival of immune effector cells, particularly CAR-T cells, by utilizing signals transmitted by TRAF, and have developed various forms of CD30 domains (CD30L, CD30M, CD30M) centered on the TRAF-binding sites (domains 1, 2, and 3) within the CD30 domain. mut As a result of constructing CD30M and CD30S, it was confirmed that when the 57 aa region of 539-595 aa or 544-588 aa of domain 2+3 was used as the intracellular signaling domain of the chimeric antigen receptor, the antitumor efficacy and cytokine secretion ability were enhanced.
[0022] The intracellular signaling domain of the chimeric antigen receptor of the present invention uses CD30ΔS, i.e., 544-588 aa + YMNM or YMFM, which additionally includes a specific amino acid, YMNM or YMFM, in addition to the 539-595 aa or 544-588 aa region of domain 2+3. These amino acid sequences are sequences not present in wild-type CD30 and are phosphoinositide 3-kinase binding site sequences. According to one embodiment, compared to the case where only the 539-595 aa or 544-588 aa region of domain 2+3 of CD30 is used in the chimeric antigen receptor, the antitumor efficacy and cytokine secretion ability of immune effector cells were similar.
[0023] Accordingly, the chimeric antigen receptor of the present invention is characterized by significantly increasing the antitumor efficacy and cytokine secretion ability of immune effector cells by using an intracellular signaling domain comprising the sequence of the 539-595 aa region or the 544-588 aa region or the 544-588 aa + YMNM or YMFM of the domain 2+3 of CD30S.
[0024] In the present invention, the term "chimeric antigen receptor, CAR" generally refers to a fusion protein containing an extracellular domain having the ability to bind to an antigen and one or more intracellular domains. The chimeric antigen receptor may include an antigen (e.g., surface antigen, tumor-associated antigen, etc.) binding domain, a transmembrane domain, and an intracellular signaling domain. The CAR may be combined with a T cell receptor-activated intracellular domain based on target antigen specificity. Genetically modified CAR-expressing T cells can specifically identify and eliminate target antigen-expressing malignant cells.
[0025] In the present invention, the term "target antigen binding domain" generally refers to a domain capable of specifically binding to an antigen protein. For example, it may be an antibody or a fragment thereof that specifically binds to a target antigen.
[0026] In the present invention, the term "binding domain" may be used interchangeably with "extracellular domain," "extracellular binding domain," "antigen-specific binding domain," and "extracellular antigen-specific bidding domain," and refers to a CAR domain or fragment having the ability to specifically bind to a target antigen.
[0027] The above target antigen may be a surface antigen or tumor-associated antigen expressed in hematological cancers or solid tumors, for example, the antigen may be CD19, MUC16, MUC1, CAIX, CEA, CDS, CD7, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, BCMA, PD-1, NKp30, cytomegalovirus (CMV) infected cell antigen, EGP-2, EGP-40, EpCAM, Erb-B2, Erb-B3, Erb-B4, FBP, fetal acetylcholine receptor, folate receptor-α, GD2, GD3, HER-2, hTERT, IL-13R-α2, κ-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, NKG2D The ligand may be selected from, but is not limited to, NY-ESO-1, carcinoembryonic antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, CD24, CD47, EGFR, CD123, GPC3, CD117, Claudin 18.2, cMET, EphA2, CLL-1, CD171, AXL, ROR2, FAP, or CD5.
[0028] In the present invention, the antibody that specifically binds to a target antigen may be a monoclonal antibody. In the present invention, the term "monoclonal antibody" is also called a monoclonal antibody or a monoclonal antibody, and is an antibody produced by a single antibody-forming cell that has a uniform primary structure (amino acid sequence). It recognizes only one antigenic determinant and is generally produced by culturing a hybridoma cell formed by fusing a cancer cell and an antibody-producing cell, but it may also be produced using another recombinant protein-expressing host cell by utilizing the obtained antibody gene sequence.
[0029] In the present invention, the term "antibody" may be used not only as a complete form having two full-length light chains and two full-length heavy chains, but also as a fragment of an antibody molecule. A fragment of an antibody molecule refers to a fragment having at least a peptide tag (epitope) binding function and includes scFv, Fab, F(ab'), F(ab')2, a single domain, etc.
[0030] Among the antibody fragments, Fab has a structure having variable regions of the light and heavy chains, a constant region of the light chain, and a first constant region (CH1) of the heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the heavy chain CH1 domain. The F(ab')2 antibody is generated when the cysteine residues in the hinge region of Fab' form disulfide bonds. The recombinant technology for generating the Fv fragment from a minimal antibody fragment having only a heavy chain variable region and a light chain variable region is disclosed in international patents WO 88 / 10649, WO 88 / 106630, WO 88 / 07085, WO 88 / 07086, and WO 88 / 09344. In double-stranded Fv (dsFv), the variable region of the heavy chain and the variable region of the light chain are connected by a disulfide bond, and in single-stranded Fv (scFv), the variable region of the heavy chain and the variable region of the light chain are generally connected by a covalent bond through a peptide linker. These antibody fragments can be obtained using proteases (for example, restriction cleavage of the whole antibody with papain yields Fab, and cleavage with pepsin yields the F(ab')2 fragment). Preferably, they can be produced using recombinant DNA technology.
[0031] In the present invention, the term “humanized antibody” is an antibody having an amino acid sequence corresponding to that of an antibody produced by a human and / or produced using one of the techniques for producing human antibodies as disclosed herein. This definition of humanized antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0032] In addition, the proteins, polypeptides, and / or amino acid sequences included in the present invention should be understood to include at least functional variants or homologs having the same or similar function as the protein or polypeptide.
[0033] In the present invention, functional variants may be proteins or polypeptides obtained by substituting, deleting, or adding one or more amino acids in the amino acid sequence of said protein and / or polypeptide. For example, functional variants may comprise proteins or polypeptides having different amino acid sequences due to the substitution, deletion, and / or insertion of one or more amino acids, such as 1 to 30, 1 to 20, 1 to 10, or 1, 2, 3, 4, or 5. Functional variants may substantially retain the biological properties of the unmodified protein or polypeptide (substitution, deletion, or addition). For example, functional variants may retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity (such as antigen binding ability) of the original protein or polypeptide.
[0034] In the present invention, the homolog may be a protein or polypeptide (e.g., an antibody capable of specifically binding to BCMA or a fragment thereof) having an amino acid sequence homology of about 85% or more with the protein and / or polypeptide (e.g., about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
[0035] In the present invention, homology generally refers to similarity, similarity, or correlation between two or more sequences.
[0036] In the present invention, the term "transmembrane domain" generally refers to a domain of a CAR that passes through the cell membrane and connects to an intracellular signaling domain to perform a role in signal transduction. The transmembrane domain is connected between the C-terminus of the target antigen binding domain and the N-terminus of the intracellular signaling domain, and may be a transmembrane domain of a TCR co-receptor or T cell co-stimulator selected from the group consisting of CD8, 4-1BB, CD27, CD28, CD30, 0X40, CD3e, CD3ζ, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and ICOS (CD278), or may be derived therefrom. Specifically, the transmembrane domain of CD28 may be used.
[0037] A hinge region may be connected between the C-terminus of the target antigen binding domain and the N-terminus of the transmembrane domain, and the hinge region may be derived from CD8α or CD28. The "hinge region" generally refers to the connection region between the antigen-binding region and the immune cell Fc receptor (FcR)-binding region.
[0038] In the present invention, the term "intracellular signal transduction domain" generally refers to a domain located inside a cell and capable of transmitting signals. The present invention may use CD30S as an intracellular signal transduction domain, including the 539-595 aa region of domain 2+3 or the deletion region thereof, 544-588 aa, among the TRAF binding sites of CD30, as well as additionally including a specific amino acid, YMNM or YMFM, at the 544-588 aa region. More specifically, it may include the amino acid sequence of SEQ ID NO: 44, 46, 48, or 50.
[0039] The chimeric antigen receptor of the present invention may be used as a third-generation chimeric antigen receptor by further including an intracellular signaling domain (or co-stimulation domain) selected from the group consisting of CD27, CD28, 4-1BB (CD137), 0X40, CD40, ICOS, LFA-1 (lymphocyte function-associated antigen-1), CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40, and KIR2DS2.
[0040] The CD3ζ intracellular signaling domain of the chimeric antigen receptor of the present invention may have an amino acid sequence of SEQ ID NO: 18 corresponding to 154-492 nucleotides derived from CD3ζ (NCBI NM_198053.2), but is not limited thereto.
[0041] In addition, the chimeric antigen receptor of the present invention may further include a signal peptide at the N-terminus of the target antigen binding domain, and the "signal peptide" generally refers to a peptide chain for guiding protein delivery. The signal peptide may use a GM-CSF receptor signal sequence, a CD8α signal sequence, an immunoglobulin heavy chain signal sequence, a PD-1 signal sequence, an NKp30 signal sequence, etc., but is not limited thereto.
[0042] According to one embodiment of the present invention, the chimeric antigen receptor of the present invention may be a second-generation chimeric antigen receptor in which a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; an intracellular signaling domain derived from CD30; and a CD3ζ intracellular signaling domain are sequentially linked.
[0043] According to another embodiment of the present invention, the chimeric antigen receptor of the present invention may be a third-generation chimeric antigen receptor in which a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; an intracellular signaling domain derived from CD30; an intracellular signaling domain (co-stimulation domain) selected from the group consisting of CD27, CD28, 4-1BB (CD137), 0X40, CD40, ICOS, LFA-1 (lymphocyte function-associated antigen-1), CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40 and KIR2DS2; and a CD3ζ intracellular signaling domain are sequentially linked.
[0044] The present invention also relates to a nucleic acid molecule encoding the chimeric antigen receptor.
[0045] The nucleic acid molecule encoding the chimeric antigen receptor may include a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; an intracellular signaling domain derived from CD30; and a polynucleotide encoding a CD3ζ intracellular signaling domain, respectively.
[0046] The nucleic acid molecule encoding the chimeric antigen receptor may include a signal peptide; a target antigen binding domain; a hinge domain; a transmembrane domain; an intracellular signaling domain selected from the group consisting of CD27, CD28, 4-1BB (CD137), 0X40, CD40, ICOS, LFA-1 (lymphocyte function-associated antigen-1), CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40 and KIR2DS2; and a polynucleotide encoding the CD3ζ intracellular signaling domain, respectively.
[0047] More specifically, the intracellular signaling domain derived from CD30 may include the nucleotide sequence of SEQ ID NO: 47 or 49.
[0048] In the present invention, the term “polynucleotide” generally refers to a nucleic acid molecule separated into any length, a deoxyribonucleotide or ribonucleotide, or an analog thereof. For example, the polynucleotide of the present invention is (1) a polymerase chain reaction (PCR) amplification, etc. in vitroIt may be prepared through amplification; (2) cloning and recombination; (3) purification such as digestion and gel electrophoresis separation; and (4) synthesis such as chemical synthesis, preferably the separated polynucleotides are prepared by recombinant DNA technology. In the present invention, the nucleic acid for encoding the antibody or its antigen-binding fragment may be prepared by various methods known in the art, including but not limited to the restriction fragment operation of synthetic oligonucleotides or the application of SOE PCR.
[0049] The present invention also relates to a vector comprising a nucleic acid molecule encoding the chimeric antigen receptor.
[0050] In the present invention, the term “expression vector” is a gene product comprising essential regulatory elements, such as a promoter, to enable a target gene to be expressed within a suitable host cell. The vector may be selected from one or more of plasmids, retroviral vectors, and lentiviral vectors. When transformed into a suitable host, the vector may replicate and function independently of the host genome, or in some cases, may be incorporated into the genome itself.
[0051] Additionally, the vector may include expression regulatory elements that enable the coding region to be accurately expressed in a suitable host. These regulatory elements are well known to those skilled in the art and may include, for example, promoters, ribosome-binding sites, enhancers, and other regulatory elements for regulating gene transcription or mRNA translation. The specific structure of the expression regulatory sequence may vary depending on the function of the species or cell type, but generally contains 5' non-transcription sequences that participate in transcription initiation and translation initiation, respectively, such as TATA boxes, capped sequences, and CAAT sequences, and 5' or 3' non-translation sequences. For example, the 5' non-transcription expression regulatory sequence may include a promoter region that may contain a promoter sequence for transcribing and regulating functionally linked nucleic acids.
[0052] The above promoter is operably linked to induce the expression of a target antigen-binding domain, wherein "operably linked" means that a nucleic acid expression-regulating sequence and a nucleic acid sequence encoding a target protein are functionally linked to perform a general function. Operatory linkage with a recombinant vector can be prepared using gene recombination technology well known in the art, and site-specific DNA cleavage and linkage can be performed using enzymes, etc., generally known in the art.
[0053] Methods for introducing and expressing genes into cells are known in the relevant art. With respect to expression vectors, the vector can be easily introduced into a host cell by any method in the relevant art. For example, an expression vector can be transferred into a host cell by physical, chemical, or biological means.
[0054] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc. Methods for producing cells containing vectors and / or exogenous nucleic acids are widely known in the relevant art. For example, the literature [Sambrook et al See , 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY.
[0055] Biological methods for introducing polynucleotides into host cells include the use of DNA and RNA vectors. Viral vectors, and particularly retroviral vectors, have become the most widely used methods for inserting genes into mammalian, e.g., human, cells. Other viral vectors may be derived from lentiviruses, poxviruses, herpes simplex viruses, adenoviruses, and adeno-associated viruses.
[0056] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., artificial membrane vesicle). Other methods for the delivery of polynucleotides are available using the latest targeted delivery technologies for nucleic acids, such as targeted nanoparticles or other suitable sub-micrometer-sized delivery systems.
[0057] Where a non-viral delivery system is used, an exemplary delivery vehicle is a liposome. The use of lipid preparations is considered for the introduction of nucleic acids into host cells (in vitro, in vitro, or in vivo). In another aspect, nucleic acids may be associated with lipids. Nucleic acids associated with lipids may be encapsulated within the aqueous interior of liposomes, dotted within the lipid bilayer of liposomes, attached to liposomes via linking molecules associated with both liposomes and oligonucleotides, captured within liposomes, complexed with liposomes, dispersed in lipid-containing solutions, mixed with lipids, combined with lipids, contained as a suspension within lipids, contained or complexed with micelles, or associated with lipids. Lipids, lipid / DNA, or lipid / expression vector association compositions are not limited to any specific structure in solution.
[0058] The present invention also relates to an immune effector cell comprising the chimeric antigen receptor, a nucleic acid molecule encoding the same, or a vector comprising the nucleic acid molecule.
[0059] The above immune effector cells may be mammalian-derived cells, and preferably may be αβ T cells, γδ T cells, NK cells (including KHYG-1, NK-92 cell lines), NK T cells, or macrophages.
[0060] Immuno-effector cells expressing the above chimeric antigen receptor can be prepared by introducing the CAR vector of the present invention into immuno-effector cells, such as T cells or NK cells.
[0061] Specifically, CAR vectors can be introduced into cells by methods known in the art, such as electroporation and lipofectamine (lipofectamine 2000, Invitrogen). For example, long-term and stable expression of the CAR can be ensured by introducing a plasmid into immune effector cells by electroporation.
[0062] Immuno-effector cells for producing immune-effector cells expressing chimeric antigen receptors may be obtained from a subject, said "subject" includes a living organism (e.g., mammal) from which an immune response can be elicited. Examples of subjects include humans, dogs, cats, mice, rats, and their transgenic counterparts. T cells may be obtained from numerous sources, including peripheral blood monocytes, bone marrow, lymph node tissue, umbilical cord blood, thymic tissue, tissue from an infection site, ascites, pleural effusion, splenic tissue, and tumors.
[0063] The above T cells may be obtained from blood units collected from a subject using any of the many techniques known to a person skilled in the art, for example, Ficoll separation. Cells from the blood are obtained by separation and the separation product typically contains T cells, monocytes, granulocytes, lymphocytes including B cells, other nucleated leukocytes, red blood cells, and platelets.
[0064] Cells collected by the separation and extraction method may be washed to remove the plasma fraction and place the cells in an appropriate buffer or medium for subsequent processing steps. T cells are isolated from peripheral blood lymphocytes by lysing red blood cells and depleting monocytes, for example, by centrifugation through a Percol or countercurrent centrifugation.
[0065] The present invention also relates to an antitumor composition comprising the immune effector cells.
[0066] According to one embodiment of the present invention, immune effector cells introduced with a chimeric antigen receptor comprising an intracellular signaling domain derived from CD30 exhibit specific cytotoxic activity against CD19-positive hematological cancer cell lines, BCMA-positive cell lines, EpCAM solid tumor cell lines, mesothelin-positive solid tumor cell lines, GPC3-positive solid tumor cell lines, PD-L1-positive solid tumor cell lines, B7-H6-positive cell lines, etc. Accordingly, the immune effector cells introduced with the chimeric antigen receptor of the present invention can be used for the treatment of hematological cancer or solid tumors.
[0067] The above solid tumor may be lung cancer, colorectal cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, melanoma, retinoblastoma, thymoma, stomach cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, bile duct cancer, or pancreatic cancer. Additionally, the above blood cancer may be lymphoma, leukemia, or multiple myeloma.
[0068] The above pharmaceutical composition may additionally include a pharmaceutically acceptable carrier. For oral administration, binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, colorants, flavors, etc. may be used; for injectables, buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, etc. may be mixed and used; and for topical administration, bases, excipients, lubricants, preservatives, etc. may be used.
[0069] The formulations of the above pharmaceutical composition can be prepared in various ways by mixing with the pharmaceutically acceptable carriers described above. For example, for oral administration, it can be prepared in the form of tablets, troches, capsules, ellipsis, suspensions, syrups, wafers, etc., and for injectables, it can be prepared in the form of unit dosing ampoules or multiple dosing ampoules.
[0070] In addition, the above pharmaceutical composition may include a surfactant capable of improving membrane permeability. Such surfactant may be derived from a steroid, cationic lipids such as N-[1-(2,3-dioleoyl)propyl-N,N,N-trimethylammonium chloride (DOTMA), or various compounds such as cholesterol hemisuccinate, phosphatidyl glycerol, but is not limited thereto.
[0071] The above pharmaceutical composition may be administered together with or sequentially with the aforementioned pharmacological or physiological components, and may also be administered in combination with additional conventional therapeutic agents, or sequentially or simultaneously with conventional therapeutic agents. Such administration may be a single or multiple administration. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects, taking all of the above factors into consideration, and this can be easily determined by a person skilled in the art.
[0072] The term "administration" as used in the present invention means providing the pharmaceutical composition of the present invention to a subject by any appropriate method. The pharmaceutical composition of the present invention may be administered at a therapeutically effective dose, which is the amount of the active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal, or human as conceived by a researcher, veterinarian, physician, or other clinician, i.e., an amount that induces the alleviation of symptoms of the disease or disorder being treated. It is obvious to those skilled in the art that the therapeutically effective dose and frequency of administration of the pharmaceutical composition of the present invention will vary according to the desired effect. Therefore, the optimal dose to be administered can be easily determined by those skilled in the art and may be adjusted according to various factors including the type of disease, the severity of the disease, the content of the active ingredient and other ingredients contained in the composition, the type of formulation, the patient's age, weight, general health condition, gender and diet, the time of administration, the route of administration and the secretion rate of the composition, the duration of treatment, and drugs used concurrently. The pharmaceutical composition of the present invention can be administered in an amount of 1 to 10,000 mg / kg / day, and may be administered once a day or divided into several doses.
[0073] As used herein, the term "subject" means a mammal suffering from or at risk of having a condition or disease that can be alleviated, suppressed, or treated by administering the pharmaceutical composition, and preferably means a human.
[0074] Accordingly, the present invention also provides a method for treating cancer comprising the step of administering a therapeutically effective amount of immune effector cells to a subject in need thereof.
[0075] The above-mentioned immune effector cells can be administered in a pharmaceutically effective amount to treat cancer in which tumor antigens are expressed. This may vary depending on various factors such as the type of disease, patient age, weight, characteristics and severity of symptoms, type of current treatment, frequency of treatment, form and route of administration, and can be easily determined by experts in the relevant field.
[0076] The above-mentioned object is the same as the target for administration of the pharmaceutical composition of the present invention.
[0077] The present invention will be explained in more detail below through embodiments according to the present invention, but the scope of the present invention is not limited by the embodiments presented below.
[0078] <Example 1> Preparation of Chimeric Antigen Receptor
[0079] (Human cell line)
[0080] Human multiple myeloma cell line IM-9, human lymphoma cell line U937 mock , U937 CD19 Human Burkitt lymphoma cell line Raji, human lung cancer cell lines NCI-H292 and NCI-H460, and human pancreatic cancer cell line AsPC-1 were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) containing 10% FBS. Human liver cancer cell line HepG2, human lung cancer cell lines A549 and Calu-1, and human head and neck cancer cell line FaDu were maintained in DMEM (Gibco) containing 10% FBS. Human ovarian cancer cell line SKOV3 was maintained in McCoy (Gibco) containing 10% FBS. Natural killer cell lines KHYG-1 and NK-92 were maintained in RPMI-1640 containing 10% FBS and 300 U / ml of interleukin-2 (IL-2). Alpha-beta T cells were maintained in RPMI-1640 containing 10% FBS and IL-2 500 U / ml. Gamma-delta T cells were cultured in RPMI-1640 containing 10% FBS and IL-2 1000 U / ml.
[0081] (Human Alpha-Beta T Cell and Gamma-Delta T Cell Culture)
[0083] For alpha-beta T cell culture, peripheral blood mononuclear cells (PBMCs) were placed in culture dishes conjugated with anti-CD3 antibodies (2 µg / ml) and anti-CD28 antibodies (2 µg / ml) and cultured in RPMI-1640 (10% FBS) containing 300 U / ml of interleukin (IL)-2 in a 37°C incubator for 7 days. Subculture was performed with fresh culture medium every 2-3 days. On the 7th day, the number of alpha-beta T cells was measured and frozen in a freezing solution consisting of 10% dimethyl sulfoxide (DMSO) and 90% fetal bovine serum (FBS).
[0084] To culture gamma delta T cells, peripheral blood monocytes were added to a culture medium containing 5 μM zoledronic acid and 500 U / ml IL-2 and cultured in a 37°C incubator for 7 days. Subculture was performed every 2-3 days with fresh medium. After counting the number of gamma delta T cells on the 7th day, feeder cells irradiated with 120 Gy X-ray intensity were co-cultured for 7 days at a gamma delta T cell:feeder cell ratio of 2:1. After 14 days of culture, the number of gamma delta T cells was measured, and they were frozen in the same freezing medium as described above.
[0085] (Plasmid)
[0086] - CD19 scFv
[0087] The signal sequence (GM-CSF receptor signal sequence), the light chain variable (VL) and heavy chain variable (VH) regions of the FMC63 anti-CD19 antibody, the hinge and transmembrane domains of CD28; the hinge and transmembrane domains of CD8α; the hinge and transmembrane domains of CD28; intracellular signaling domains; and the intracellular signaling domains of CD28, CD30 and various mutants of CD30, 4-1BB, CD27, ICOS, OX40, and CD3ζ (CD3z) were each artificially synthesized. These were assembled in various combinations using overlapping extension by PCR. The PCR products amplified by ligating XhoI, EcoRV, and NotI sequences to both ends were inserted (fusion cloning, ligation) into the XhoI and NotI sites of the pCI vector (pCI Mammalian Expression vector, Promega E1731). The PCR products were verified by sequencing.
[0088] - BCMA
[0089] The signal sequence (GM-CSF receptor signal sequence) and the light chain variable (VL) and heavy chain variable (VH) regions of the Bb2121 anti-BCMA antibody, the hinge and transmembrane domains of CD28; intracellular signaling domains; mutants of CD28, 4-1BB, and CD30, and the intracellular signaling domain of CD3ζ (CD3z) were each artificially synthesized. As with the CD19 scFv above, they were assembled using PCR, inserted into a pCI vector, and the PCR products were verified by sequencing.
[0090] - EpCAM
[0091] The scFv signal sequence (CD8α signal sequence) and the light chain variable (VL) and heavy chain variable (VH) regions of the VB4-845 anti-EpCAM antibody, the hinge and transmembrane domains of CD8α; the hinge and transmembrane domains of CD28; the intracellular signaling domains; mutants of CD28, 4-1BB, and CD30, and the intracellular signaling domains of CD3ζ (CD3z) were each artificially synthesized. As with the CD19 scFv above, they were assembled using PCR, inserted into a pCI vector, and the PCR products were verified by sequencing.
[0092] - Mesothelin
[0093] The scFv signal sequence (GM-CSF receptor signal sequence) and the light chain variable (VL) and heavy chain variable (VH) regions of the MORAb-009 anti-Mesothelin antibody, the hinge and transmembrane domains of CD8α; the hinge and transmembrane domains of CD28; the intracellular signaling domains; mutants of CD28, 4-1BB, and CD30, and the intracellular signaling domains of CD3ζ (CD3z) were each artificially synthesized. As with the CD19 scFv above, they were assembled using PCR, inserted into a pCI vector, and the PCR products were verified by sequencing.
[0094] - Glypican-3
[0095] Immunoglobulin heavy-chain signal sequences and the light chain variable (VL) and heavy chain variable (VH) regions of the GC33 anti-Glypican-3 antibody, the hinge and transmembrane domains of CD28; intracellular signaling domains; mutants of CD28, 4-1BB, and CD30, and the intracellular signaling domain of CD3ζ (CD3z) were each artificially synthesized. As with the CD19 scFv above, they were assembled using PCR, inserted into a pCI vector, and the PCR products were verified by sequencing.
[0096] - PD-1 ECD
[0097] The signal sequence and extracellular domain, hinge, and transmembrane domain of PD-1; the intracellular signaling domain; mutants of CD28, 4-1BB, and CD30, and the intracellular signaling domain of CD3ζ (CD3z) were each artificially synthesized. As with the CD19 scFv above, they were assembled using PCR, inserted into a pCI vector, and the PCR products were verified by sequencing.
[0098] - NKp30
[0099] The signal sequence and extracellular domain, hinge, and transmembrane domain of NKp30; the intracellular signaling domain; mutants of CD28, 4-1BB, and CD30, and the intracellular signaling domain of CD3ζ (CD3z) were each artificially synthesized.
[0100] As with the CD19 scFv mentioned above, it was assembled using PCR, inserted into a pCI vector, and the PCR product was verified by sequencing.
[0101] The chimeric antigen receptors (CARs) described above are listed in Tables 1 to 13, and their sequences are listed in Table 14. All CAR domains are connected in tandem and also connected in frame.
[0102] 2nd Generation CAR Targeting CD19: CD30 Domain Screening Abbreviation Signal sequence scFv hinge TM Signal-1 Signal-2 CD19-28S-z GM-CSF rec FMC63 anti-CD19 CD28 CD28 CD28 CD3ζ CD19-30L-z GM-CSF rec FMC63 anti-CD19 CD8α CD28 CD30L CD3ζ CD19-30M-z GM-CSF rec FMC63 anti-CD19 CD8α CD28 CD30M CD3ζ CD19-30M Mut -With GM-CSF rec FMC63 anti-CD19 CD8α CD28 CD30M Mut CD3ζ CD19-30ΔM-z GM-CSF rec FMC63 anti-CD19 CD8α CD28 CD30ΔM CD3ζ CD19-30S-z GM-CSF rec FMC63 anti-CD19 CD8α CD28 CD30S CD3ζ
[0104] As illustrated in Table 1, CD19-28-z is the signal sequence domain of the human GM-CSF receptor (1-66 nucleotides (nt), NCBI Reference Sequence ID: 001161531.2); the light chain variable (VL) region and heavy chain variable (VH) of the FMC63 anti-CD19 antibody (KR10-2019-7034220 / WO2018 / 200496 JS scFv); the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28; and the intracellular signaling domain (538-660 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28. and an intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2) and the stop codon TAA are linked.
[0105] CD19-30L-z is identical to CD19-28-z except that it uses a hinge derived from human CD8α (412-546 nt, NCBI Reference Sequence: NM_001768) and an intracellular signaling domain derived from human CD30 (1219-1785 nt, NCBI Reference Sequence: NM_001243.3).
[0106] CD19-30M-z is identical to CD19-28-z except that it uses a hinge derived from human CD8α (412-546 nt, NCBI Reference Sequence: NM_001768) and a truncated mutant of the intracellular signaling domain derived from human CD30 (1501-1785 nt, NCBI Reference Sequence: NM_001243.3).
[0107] CD19-30M Mut-z is identical to CD19-28-z except that it uses a hinge derived from human CD8α (412-546 nt, NCBI Reference Sequence: NM_001768) and a truncated mutant of the intracellular signaling domain derived from human CD30 (521 amino acid K→Q of 1501-1785 nt, NCBI Reference Sequence: NM_001243.3).
[0108] CD19-30ΔM-z is identical to CD19-28-z except that it uses a hinge derived from human CD8α (412-546 nt, NCBI Reference Sequence: NM_001768) and a truncated mutant of the intracellular signaling domain derived from human CD30 (1501-1614, 1678-1785 nt, NCBI Reference Sequence: NM_001243.3).
[0109] CD19-30S-z is identical to CD19-28-z except that it uses a hinge derived from human CD8α (412-546 nt, NCBI Reference Sequence: NM_001768) and a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3).
[0110] 2nd Generation CAR Targeting CD19: Modified CD30S Abbreviation Signal sequence scFv Linker hinge TM Signal-1 Signal-2 CD19-30S-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30S CD3ζ CD19-30ΔS-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30ΔS CD3ζ CD19-30ΔS YN -z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30ΔS YN CD3ζ CD19-30ΔS YF -z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30ΔS YF CD3ζ
[0111] CD19-30S-z shown in Table 2 consists of the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI Reference Sequence ID: 001161531.2); the light chain variable (VL) and heavy chain variable (VH) regions of the FMC63 anti-CD19 antibody (KR10-2019-7034220 / WO2018 / 200496 JS scFv); the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28; and a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3); and an intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2, codon optimization) and the stop codon TAA are linked.
[0112] CD19-30ΔS-z is the same as CD19-30S-z in Table 2, except that a truncated mutant of the intracellular signaling domain derived from human CD30 (1630-1764 nt, NCBI Reference Sequence: NM_001243.3) was used as the first signaling domain.
[0113] CD19-30ΔS YN -z is the same as CD19-30S-z in Table 2, except that it uses a domain in which the YMNM (16 aa) region, which is part of the CD28 intracellular signaling domain, is combined with a truncated mutant of the human CD30-derived intracellular signaling domain (1630-1764 nt of CD30) as the first signaling domain.
[0114] CD19-30ΔS YF-z is the same as CD19-30S-z in Table 2, except that as the first signaling domain, a domain is used in which the YMFM (16 aa) region, which is part of the CD28 intracellular signaling domain, is combined with a truncated mutant of the human CD30-derived intracellular signaling domain (1630-1764 nt of CD30).
[0115] 2nd generation CAR targeting CD19 Abbreviation Signal sequence scFv Linker hinge TM Signal-1 Signal-2 CD19-30S-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30S CD3ζ CD19-28-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD28 CD3ζ CD19-4-1BB-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 4-1BB CD3ζ CD19-27-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD27 CD3ζ CD19-ICOS-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 ICOS CD3ζ CD19-OX40-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 OX40 CD3ζ
[0116] CD19-28-z and CD19-30S-z were constructed in the same manner as above. CD19-4-1BB-z is identical to CD19-30S-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the first intracellular signaling domain.
[0117] CD19-27-z is identical to CD19-30S-z except that it uses an intracellular signaling domain derived from human CD27 (640-780 nt, NCBI Reference Sequence: NM_001242.4) as its first signaling domain.
[0118] CD19-ICOS-z is identical to CD19-30S-z except that it uses an intracellular signaling domain derived from human ICOS (484-597 nt, NCBI Reference Sequence: NM_012092.2) as its first signaling domain.
[0119] CD19-OX40-z is identical to CD19-30S-z except that it uses an intracellular signaling domain derived from human OX40 (706-831 nt, NCBI Reference Sequence: NM_003327.2) as its first signaling domain.
[0120] 3rd generation CAR targeting CD19 Abbreviation Signal sequence scFv Linker hinge TM Signal-1 Signal-2 Signal-3 CD19-28-BB-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD28 4-1BB CD3ζ CD19-30S-BB-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30S 4-1BB CD3ζ CD19-28-30S-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD28 CD30S CD3ζ CD19-30S-ICOS-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30S ICOS CD3ζ CD19-30S-CD27-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30S CD27 CD3ζ CD19-30S-OX40-z GM-CSF rec FMC63 anti-CD19 (G4S)3 CD28 CD28 CD30S OX40 CD3ζ
[0121] CD19-28-BB-z is the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI Reference Sequence ID: 001161531.2); the light chain variable (VL) region and heavy chain variable (VH) of the FMC63 anti-CD19 antibody (KR10-2019-7034220 / WO2018 / 200496 JS scFv); the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28; and the intracellular signaling domain (538-660 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28. and an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimization); an intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2, codon optimization) and a stop codon TAA are connected.
[0122] CD19-30S-BB-z is identical to CD19-28-BB-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the co-stimulatory domain (second signaling domain).
[0123] CD19-28-30S-z is identical to CD19-28-BB-z except that it uses a hinge derived from human CD28 (340-456 nt, NCBI Reference Sequence: NM_006139.2) as the first signaling domain and a truncated mutant of an intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the co-stimulatory domain (second signaling domain).
[0124] CD19-30S-ICOS-z is identical to CD19-28-BB-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and an intracellular signaling domain derived from human ICOS (484-597 nt, NCBI Reference Sequence: NM_012092.2) as the co-stimulatory domain (second signaling domain).
[0125] CD19-30S-CD27-z is identical to CD19-28-BB-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and an intracellular signaling domain derived from human CD27 (640-780 nt, NCBI Reference Sequence: NM_001242.4) as the co-stimulatory domain (second signaling domain).
[0126] CD19-30S-OX40-z is identical to CD19-28-BB-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and an intracellular signaling domain derived from human OX40 (706-831 nt, NCBI Reference Sequence: NM_003327.2) as the co-stimulatory domain (second signaling domain).
[0127] 3rd generation CAR targeting BCMA Abbreviation Signal sequence scFv hinge TM Signal-1 Signal-2 Signal-3 BCMA-28-30S-z GM-CSF rec Anti-BCMA02 CD28 CD28 CD28 CD30S CD3ζ BCMA-28-BB-z GM-CSF rec Anti-BCMA02 CD28 CD28 CD28 4-1BB CD3ζ BCMA-30S-BB-z GM-CSF rec Anti-BCMA02 CD28 CD28 CD30S 4-1BB CD3ζ
[0128] BCMA-28-30S-z is the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI Reference Sequence ID: 001161531.2); the light chain variable (VL) and heavy chain variable (VH) regions of the Bb2121 anti-BCMA antibody (KR10-2021-7003369 / WO2020 / 014333); the transmembrane domain derived from human CD28 (457-537 nt, NCBI Reference Sequence: NM_006139.2); the intracellular signaling domain derived from human CD28 (538-660 nt, NCBI Reference Sequence: NM_006139.2); and a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3); It is a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2) linked with the stop codon TAA.
[0129] BCMA-28-BB-z is identical to BCMA-28-30S-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain (co-stimulatory domain).
[0130] BCMA-30S-BB-z is identical to BCMA-28-30S-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain (co-stimulatory domain).
[0131] 2nd generation CAR targeting EpCAM Abbreviation Signal sequence scFv Linker hinge TM Signal-1 Signal-2 EpCAM-28-z CD8α VB4-845 (G4S)3 CD28 CD28 CD28 CD3ζ EpCAM-BB-z CD8α VB4-845 (G4S)3 CD28 CD28 4-1BB CD3ζ EpCAM-30S-z CD8α VB4-845 (G4S)3 CD28 CD28 CD30S CD3ζ EpCAM-28TM CD8α VB4-845 (G4S)3 CD28 CD28 - -
[0132] EpCAM-28-z comprises the signal sequence domain of human CD8α (1-63 nt, NCBI Reference Sequence ID: NM_001768.5); the light chain variable (VL) region of the optimized VB4-845 anti-EpCAM antibody (PCT / CA2008 / 001680); and the heavy chain variable (VH) region (PCT / CA2008 / 001680); the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28; and the intracellular signaling domain (538-660 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28. It is a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2) linked with the stop codon TAA.
[0133] EpCAM-BB-z is identical to EpCAM-28-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as its first signaling domain.
[0134] EpCAM-30S-z is identical to EpCAM-28-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as its first signaling domain.
[0135] EpCAM-28TM is identical to EpCAM-28-z except that it does not include the first signaling domain and the second signaling domain.
[0136] 3rd generation CAR targeting EpCAM Abbreviation Signal sequence scFv Linker hinge TM Signal-1 Signal-2 Signal-3 EpCAM-28-30S-z CD8α VB4-845 (G4S)3 CD28 CD28 CD28 CD30S CD3ζ EpCAM-28-BB-z CD8α VB4-845 (G4S)3 CD28 CD28 CD28 4-1BB CD3ζ EpCAM-30S-BB-z CD8α VB4-845 (G4S)3 CD28 CD28 CD30S 4-1BB CD3ζ
[0137] EpCAM-28-30S-z comprises the signal sequence domain of human CD8α (1-63 nt, NCBI Reference Sequence ID: NM_001768.5); the light chain variable (VL) region of the optimized VB4-845 anti-EpCAM antibody (PCT / CA2008 / 001680); and the heavy chain variable (VH) region (PCT / CA2008 / 001680); the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28; and the intracellular signaling domain (538-660 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28. A truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3); an intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2, codon optimization) and a stop codon TAA are linked.
[0138] EpCAM-28-BB-z is identical to EpCAM-28-30S-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain (co-stimulatory domain).
[0139] EpCAM-30S-BB-z is identical to EpCAM-28-30S-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain (co-stimulatory domain).
[0140] 2nd generation CAR targeting MSLN Abbreviation Signal sequence scFv Linker hinge TM Signal-1 Signal-2 MSLN(MOR)-28-z GM-CSF rec MORAb-009 (G4S)3 CD28 CD28 CD28 CD3ζ MSLN(MOR)-BB-z GM-CSF rec MORAb-009 (G4S)3 CD28 CD28 4-1BB CD3ζ MSLN(MOR)-30S-z GM-CSF rec MORAb-009 (G4S)3 CD28 CD28 CD30S CD3ζ
[0141] MSLN(MOR)-28-z consists of the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI Reference Sequence ID: 001161531.2); the heavy chain variable (VH) region (amatuximab, chimeric monoclonal antibody; gamma1 heavy chain, 1-119) and light chain variable (VL) region (amatuximab, chimeric monoclonal antibody; kappa light chain 1-106) of the MORAb-009 anti-Mesothelin antibody; and the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28. It is a human CD28-derived intracellular signaling domain (538-660 nt, NCBI Reference Sequence: NM_006139.2); a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2) linked with the stop codon TAA.
[0142] MSLN(MOR)-BB-z is identical to MSLN(MOR)-28-z except that it uses an intracellular signaling domain derived from human CD137(4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as its first signaling domain.
[0143] MSLN(MOR)-30S-z is identical to MSLN(MOR)-28-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as its first signaling domain.
[0144] 3rd generation CAR targeting MSLN Abbreviation Signal sequence scFv Linker hinge TM Signal-1 Signal-2 Signal-3 MSLN(MOR)-28-30S-z GM-CSF rec MORAb-009 (G4S)3 CD28 CD28 CD28 CD30S CD3ζ MSLN(MOR)-28-BB-z GM-CSF rec MORAb-009 (G4S)3 CD28 CD28 CD28 4-1BB CD3ζ MSLN(MOR)-30S-BB-z GM-CSF rec MORAb-009 (G4S)3 CD28 CD28 CD30S 4-1BB CD3ζ
[0145] MSLN(MOR)-28-30S-z is the signal sequence domain of the human GM-CSF receptor (1-66 nt, NCBI Reference Sequence ID: 001161531.2); the heavy chain variable (VH) region (amatuximab, chimeric monoclonal antibody; gamma1 heavy chain, 1-119) and light chain variable (VL) region (amatuximab, chimeric monoclonal antibody; kappa light chain 1-106) of the MORAb-009 anti-Mesothelin antibody; the hinge (340-456 nt, NCBI Reference Sequence: NM_006139.2) and transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2) derived from human CD28; It is a combination of an intracellular signaling domain derived from human CD28 (538-660 nt, NCBI Reference Sequence: NM_006139.2); a truncated mutant of an intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3); an intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2, codon optimization) and a stop codon TAA.
[0146] MSLN(MOR)-28-BB-z is identical to MSLN(MOR)-28-30S-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as its second signaling domain.
[0147] MSLN(MOR)-30S-BB-z is identical to MSLN(MOR)-28-30S-z except that it uses a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and the human CD137(4-1BB)-derived intracellular signaling domain (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain.
[0148] 3rd generation CAR targeting GPC3 Abbreviation Signal sequence scFv TM Signal-1 Signal-2 Signal-3 GPC3-28-30S-z immunoglobulin heavy-chain GC33 CD28 CD28 CD30S CD3ζ GPC3-28-BB-z immunoglobulin heavy-chain GC33 CD28 CD28 4-1BB CD3ζ GPC3-30S-BB-z immunoglobulin heavy-chain GC33 CD28 CD30S 4-1BB CD3ζ
[0149] GPC3-28-30S-z is the signal sequence domain of the human immunoglobulin heavy-chain (1-57 nt, GenBank ID: AAC18316.1); the light chain variable (VL) and heavy chain variable (VH) regions of the GC33 anti-GPC3 antibody (US2017 / 0281683); the transmembrane domain derived from human CD28 (457-537 nt, NCBI Reference Sequence: NM_006139.2); the intracellular signaling domain derived from human CD28 (538-660 nt, NCBI Reference Sequence: NM_006139.2); and a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3); It is a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2) linked with the stop codon TAA.
[0150] GPC3-28-BB-z is identical to GPC3-28-30S-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as its second signaling domain.
[0151] GPC3-30S-BB-z is identical to GPC3-28-30S-z except that it uses a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and the human CD137 (4-1BB)-derived intracellular signaling domain (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain.
[0152] 2nd generation CAR targeting PD-L1 Abbreviation Signal sequence ECD TM Signal-1 Signal-2 PD-1-28-z PD-1 PD-1 PD-1 5aa+CD28 CD28 CD3ζ PD-1-BB-z PD-1 PD-1 PD-1 5aa+CD28 4-1BB CD3ζ PD-1-30S-z PD-1 PD-1 PD-1 5aa+CD28 CD30S CD3ζ PD-1-28TM PD-1 PD-1 PD-1 5aa+CD28 - -
[0153] PD-1-28-z is the human PD-1 signal sequence domain (1-60 nt, NCBI Reference Sequence: NM_005018.2); the human PD-1 extracellular domain (61-510 nt, NCBI Reference Sequence: NM_005018.2); the human PD-1 transmembrane domain (511-525 nt, NCBI Reference Sequence: NM_005018.2); the human CD28-derived transmembrane domain (457-537 nt, NCBI Reference Sequence: NM_006139.2); and the human CD28-derived intracellular signaling domain (538-660 nt, NCBI Reference Sequence: NM_006139.2); It is a human CD3z-derived intracellular signaling domain (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2) linked with the stop codon TAA.
[0154] PD-1-4-1BB-z is identical to PD-1-28-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as its first signaling domain.
[0155] PD-1-30S-z is identical to PD-1-28-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as its first signaling domain.
[0156] PD-1-28TM is identical to PD-1-28-z except that it lacks a first signaling domain and a second signaling domain.
[0157] 3rd generation CAR targeting PD-L1 Abbreviation Signal sequence ECD hinge TM Signal-1 Signal-2 Signal-3 PD-1-28-30S-z PD-1 PD-1 CD28 PD-1 5aa +CD28 CD28 CD30S CD3ζ PD-1-28-BB-z PD-1 PD-1 CD28 PD-1 5aa +CD28 CD28 4-1BB CD3ζ PD-1-30S-BB-z PD-1 PD-1 CD28 PD-1 5aa +CD28 CD30S 4-1BB CD3ζ
[0158] PD-1-28-30S-z is the signal sequence domain of human PD-1 (1-60 nt, NCBI Reference Sequence:NM_005018.2); the extracellular domain of human PD-1 (61-510 nt, NCBI Reference Sequence: NM_005018.2); the transmembrane domain of human PD-1 (511-525 nt, NCBI Reference Sequence: NM_005018.2); the transmembrane domain derived from human CD28 (457-537 nt, NCBI Reference Sequence: NM_006139.2); and the intracellular signaling domain derived from human CD28 (538-660 nt, NCBI Reference Sequence: NM_006139.2); A truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3); an intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2, codon optimization) and a stop codon TAA are linked.
[0159] PD-1-28-BB-z is identical to PD-1-28-30S-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as its second signaling domain.
[0160] PD-1-30S-BB-z is identical to PD-1-28-30S-z except that it uses a truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain.
[0161] 3rd generation CAR targeting human B7-H6 antigen Abbreviation Signal sequence ECD TM Signal-1 Signal-2 Signal-3 NKp30-28-30S-z NKp30 NKp30 NKp30 5aa+CD28 CD28 CD30S CD3ζ NKp30-28-BB-z NKp30 NKp30 NKp30 5aa+CD28 CD28 4-1BB CD3ζ NKp30-30S-BB-z NKp30 NKp30 NKp30 5aa+CD28 CD30S 4-1BB CD3ζ
[0162] NKp30-28-30S-z is the signal sequence domain of human NKp30 (1-54 nt, NCBI Reference Sequence ID: NM_147130.1); the extracellular domain of human NKp30 (55-405 nt, NCBI Reference Sequence NM_147130.1); the transmembrane domain derived from human NKp30 (406-420 nt, NCBI Reference Sequence: NM_147130.1); the transmembrane domain derived from human CD28 (457-537 nt, NCBI Reference Sequence: NM_006139.2); and the intracellular signaling domain derived from human CD28 (538-660 nt, NCBI Reference Sequence: NM_006139.2); A truncated mutant of the intracellular signaling domain derived from human CD30 (1615-1785 nt, NCBI Reference Sequence: NM_001243.3); an intracellular signaling domain derived from human CD3z (154-492 nt, 50th_Q deletion, NCBI Reference Sequence: NM_198053.2, codon optimization) and a stop codon TAA are linked.
[0163] NKp30-28-BB-z is identical to NKp30-28-30S-z except that it uses an intracellular signaling domain derived from human CD137 (4-1BB) (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as its second signaling domain.
[0164] NKp30-30S-BB-z is identical to NKp30-28-30S-z except that it uses a truncated mutant of the human CD30-derived intracellular signaling domain (1615-1785 nt, NCBI Reference Sequence: NM_001243.3) as the first signaling domain and the human CD137 (4-1BB)-derived intracellular signaling domain (640-765 nt, NCBI Reference Sequence: NM_001561.4, codon optimized) as the second signaling domain.
[0165] Sequence list of the chimeric antigen receptor and the domains used in its manufacture as described in the examples Sequence number Ranking name Explanation of the order 1 GM-SCF rec LS nucleotide nucleotide sequence of the human GM-CSF receptor signaling sequence domain 2 GM-SCF rec LS amino acid Amino acid sequence of the human GM-CSF receptor signaling sequence domain 3 CD19 VL nucleotide CD19 single-strand fragment variable-light-strand variable nucleotide sequence 4 CD19 VL amino acid Amino acid sequence of CD19 single-strand fragment variable - light-strand variable 5 Linker nucleotide nucleotide sequence of the linker connecting CD19 VL and CD19 VH 6 Linker amino acid Amino acid sequence of the linker connecting CD19 VL and CD19 VH 7 CD19 VH nucleotide CD19 single-strand variable-heavy-strand variable nucleotide sequence 8 CD19 VH amino acid Amino acid sequence of CD19 single-strand fragment variable-heavy-strand variable 9 Linker nucleotide Nucleotide sequence of the linker connecting CD19 scFv and the hinge (gcggccgca) 10 Linker amino acid Amino acid sequence (AAA) of the linker connecting the CD19 scFv and the hinge 11 CD28 Hinge nucleotide Nucleotide sequence of the spacer domain derived from CD28 12 CD28 Hinge amino acid Amino acid sequence of the linkage domain derived from CD28 13 CD28™ nucleotide Nucleotide sequence of the transmembrane domain derived from CD28 14 CD28™ amino acid Amino acid sequence of the CD28-derived transmembrane domain 15 CD28 ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD28 16 CD28 ICD amino acid Amino acid sequence of the intracellular signaling domain derived from CD28 17 CD3z nucleotide Nucleotide sequence of the intracellular signaling domain (Δ301-303) derived from CD3z 18 CD3z amino acid Amino acid sequence of the intracellular signaling domain (Δ101) derived from CD3z 19 CD19-28-z nucleotide Nucleotide sequence of CD19-28-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28 ICD-CD3 zeta) 20 CD19-28-z amino acid Amino acid sequence of CD19-28-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28 ICD-CD3 zeta) 21 CD8α Hinge nucleotide nucleotide sequence of the linkage domain derived from CD8α 22 CD8α Hinge amino acid Amino acid sequence of the linkage domain derived from CD8α 23 CD30L ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 189aa) 24 CD30L ICD amino acid Amino acid sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 189aa) 25 CD3z nucleotide Codon-optimized nucleotide sequence of the CD3z-derived intracellular signaling domain (Δ301-303) 26 CD3z amino acid Codon-optimized amino acid sequence of the CD3z-derived intracellular signaling domain (Δ101) 27 CD19-30L-z nucleotide Nucleotide sequence of CD19-30L-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-CD30L ICD-CD3 zeta) 28 CD19-30L-z amino acid Amino acid sequence of CD19-30L-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-CD30L ICD-CD3 zeta) 29 RSK nucleotide Nucleotide sequence of 3 amino acids derived from CD28 (aggagcaag) 30 RSK amino acid CD28-derived 3-amino acid sequence (RSK) 31 CD30M ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 95aa) 32 CD30M ICD amino acid Amino acid sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 95aa) 33 CD19-30M-z nucleotide Nucleotide sequence of CD19-30M-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-RSK-CD30M ICD-CD3 zeta) 34 CD19-30M-z amino acid Amino acid sequence of CD19-30M-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-RSK-CD30M ICD-CD3 zeta) 35 CD30M mut ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 95aa, 521_KQ) 36 CD30M mut ICDamino acid Amino acid sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 95aa, 521_KQ) 37 CD19-30M mut -z nucleotide CD19-30M mut -z CAR nucleotide sequence(hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-RSK-CD30M mut ICD-CD3 zeta) 38 CD19-30M mut -z amino acid Amino acid sequence of CD19-30Mmut-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-RSK-CD30M mut ICD-CD3 zeta) 39 CD30ΔM ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 73aa) 40 CD30ΔM ICD amino acid Amino acid sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 73aa) 41 CD19-30ΔM-z nucleotide Nucleotide sequence of CD19-30ΔM -z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-RSK-ΔCD30M ICD-CD3 zeta) 42 CD19-30ΔM-z amino acid Amino acid sequence of CD19-30ΔM -z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8α Hinge-CD28 TM-RSK-ΔCD30M ICD-CD3 zeta) 43 CD30S ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 57aa) 44 CD30S ICD amino acid Amino acid sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 57aa) 45 CD30ΔS ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 45aa) 46 CD30ΔS ICD amino acid Amino acid sequence of the intracellular signaling domain derived from CD30 (TNFRSF8, 45aa) 47 CD30ΔS YN ICD nucleotide Nucleotide sequences of intracellular signaling domains derived from CD30 (TNFRSF8, 45aa) and CD28 (YMNM, 16aa) 48 CD30ΔS YN ICD amino acid Amino acid sequences of intracellular signaling domains derived from CD30 (TNFRSF8, 45aa) and CD28 (YMNM, 16aa) 49 CD30ΔS YF ICD nucleotide Nucleotide sequences of intracellular signaling domains derived from CD30 (TNFRSF8, 45aa) and CD28 (YMFM, 16aa) 50 CD30ΔS YF ICD amino acid Amino acid sequences of intracellular signaling domains derived from CD30 (TNFRSF8, 45aa) and CD28 (YMFM, 16aa) 51 CD19-30S-z nucleotide Nucleotide sequence of CD19-30S-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8a Hinge-CD28 TM-RSK-CD30S ICD-CD3 zeta) 52 CD19-30S-z amino acid Amino acid sequence of CD19-30S-z CAR (hGMCSF rec LS-CD19 VL-linker-CD19 VH-AAA-CD8a Hinge-CD28 TM-RSK-CD30S ICD-CD3 zeta) 53 (G4S)3 linker nucleotide nucleotide sequence of the linker connecting CD19 VL and CD19 VH 54 (G4S)3 linker amino acid Amino acid sequence of the linker connecting CD19 VL and CD19 VH 55 CD19-30S-z nucleotide Nucleotide sequence of CD19-30S-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-CD3 zeta) 56 CD19-30S-z amino acid Amino acid sequence of CD19-30S-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-CD3 zeta) 57 CD19-CD30ΔS-z nucleotide Amino acid sequence of CD19-CD30ΔS-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30ΔS ICD-CD3 zeta) 58 CD19-CD30ΔS-z amino acid Amino acid sequence of CD19-CD30ΔS-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30ΔS ICD-CD3 zeta) 59 CD19-CD30ΔS YN -z nucleotide Amino acid sequence of CD19-CD30ΔS YN-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30ΔS YN ICD-CD3 zeta) 60 CD19-CD30ΔS YN -z amino acid Amino acid sequence of CD19-CD30ΔS YN-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30ΔS YN ICD-CD3 zeta) 61 CD19-CD30ΔS YF -z nucleotide Amino acid sequence of CD19-CD30ΔS YF-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30ΔS YF ICD-CD3 zeta) 62 CD19-CD30ΔS YF -z amino acid Amino acid sequence of CD19-CD30ΔS YF-z Chimeric Antigen Receptor (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30ΔS YF ICD-CD3 zeta) 63 CD19-28-z nucleotide Nucleotide sequence of CD19-28-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28 ICD-CD3 zeta) 64 CD19-28-z amino acid Amino acid sequence of CD19-28-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28 ICD-CD3 zeta) 65 4-1BB(CD137) ICD nucleotide Codon-optimized nucleotide sequence of intracellular signaling domain derived from 4-1BB (CD137, TNFRSF9) 66 4-1BB(CD137) ICDamino acid Codon-optimized amino acid sequence of the intracellular signaling domain derived from 4-1BB (CD137, TNFRSF9) 67 CD19-BB-z nucleotide Nucleotide sequence of CD19-BB-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-4-1BB ICD-CD3 zeta) 68 CD19-BB-z amino acid Amino acid sequence of CD19-BB-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-4-1BB ICD-CD3 zeta) 69 CD27 ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from CD27 70 CD27 ICD amino acid Amino acid sequence of the intracellular signaling domain derived from CD27 71 hCD19-27-z nucleotide Nucleotide sequence of CD19-27-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD27 ICD-CD3 zeta) 72 hCD19-27-Z amino acid Amino acid sequence of CD19-27-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD27 ICD-CD3 zeta) 73 ICOS ICD nucleotide Nucleotide sequence of intracellular signaling domain derived from ICOS 74 ICOS ICD amino acid Amino acid sequence of intracellular signaling domain derived from ICOS 75 hCD19-ICOS-z nucleotide Nucleotide sequence of CD19-ICOS-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-ICOS ICD-CD3 zeta) 76 hCD19-ICOS-zamino acid Amino acid sequence of CD19-ICOS-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-ICOS ICD-CD3 zeta) 77 OX40 ICD nucleotide Nucleotide sequence of the intracellular signaling domain derived from OX40 78 OX40 ICD amino acid Amino acid sequence of the intracellular signaling domain derived from OX40 79 hCD19-OX40-z nucleotide Nucleotide sequence of CD19-OX40-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-OX40 ICD-CD3 zeta) 80 hCD19-OX40-zamino acid Amino acid sequence of CD19-OX40-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-OX40 ICD-CD3 zeta) 81 hCD19-28-BB-z nucleotide Nucleotide sequence of CD19-28-BB-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 82 hCD19-28-BB-zamino acid Amino acid sequence of CD19-28-BB-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 83 hCD19-30S-BB-z nucleotide Nucleotide sequence of CD19-30S-BB-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 84 hCD19-30S-BB-zamino acid Amino acid sequence of CD19-30S-BB-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 85 hCD19-28-30S-z nucleotide Nucleotide sequence of CD19-28-30S-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28-CD30S-CD3 zeta) 86 hCD19-28-30S-Zamino acid Amino acid sequence of CD19-28-30S-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD28-CD30S-CD3 zeta) 87 hCD19-30S-ICOS-Z nucleotide Nucleotide sequence of CD19-30S-ICOS-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-ICOS ICD-CD3 zeta) 88 hCD19-30S-ICOS-Zamino acid Amino acid sequence of CD19-30S-ICOS-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-CD30S-RSK-CD27 ICD-CD3 zeta) 89 hCD19-30S-27-Z nucleotide Nucleotide sequence of CD19-30S-27-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-CD27 ICD-CD3 zeta) 90 hCD19-30S-27-Zamino acid Amino acid sequence of CD19-30S-27-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-CD27 ICD-CD3 zeta) 91 hCD19-30S-OX40-Z nucleotide Nucleotide sequence of CD19-30S-OX40-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-OX40 ICD-CD3 zeta) 92 hCD19-30S-OX40-Zamino acid Amino acid sequence of CD19-30S-27-z CAR (hGMCSF rec LS-CD19 VL-(G4S)3 linker-CD19 VH-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-OX40 ICD-CD3 zeta) 93 CD8α LS nucleotide nucleotide sequence of the human CD8α signal sequence domain 94 CD8α LS amino acid Amino acid sequence of the human CD8α signaling sequence domain 95 EpCAM VL nucleotide EpCAM single-chain fragment variable-light-chain variable nucleotide sequence 96 EpCAM VL amino acid amino acid sequence of EpCAM single-chain fragment variable-light-chain variable 97 EpCAM VH nucleotide EpCAM single-strand variable-heavy-strand variable nucleotide sequence 98 EpCAM VH amino acid amino acid sequence of EpCAM single-chain fragment variable-heavy-chain variable 99 EpCAM-28-z nucleotide Nucleotide sequence of EpCAM-28-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-CD28 ICD-CD3 zeta) 100 EpCAM-28-z amino acid Amino acid sequence of EpCAM-28-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-CD28 ICD-CD3 zeta) 101 EpCAM-BB-z nucleotide Nucleotide sequence of EpCAM-BB-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-RSK-4-1BB ICD-CD3 zeta) 102 EpCAM-BB-z amino acid Amino acid sequence of EpCAM-BB-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-RSK-4-1BB ICD-CD3 zeta) 103 EpCAM-30S-z nucleotide Nucleotide sequence of EpCAM-30S-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-RSK-CD30S ICD-CD3 zeta) 104 EpCAM-30S-z amino acid Amino acid sequence of EpCAM-30S-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-RSK-CD30S ICD-CD3 zeta) 105 EpCAM-28™ nucleotide Nucleotide sequence of EpCAM-28TM (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-RSK-AA) 106 EpCAM-28™ amino acid Amino acid sequence of EpCAM-28TM (hCD8a LS-EpCAM VL-(G4S)3 linker- EpCAM VH-CD28 Hinge-CD28 TM-RSK-AA) 107 EpCAM-28-30S-z nucleotide Nucleotide sequence of EpCAM-28-30S-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-CD28 ICD-CD30S ICD-CD3 zeta) 108 EpCAM-28-30S-zamino acid Amino acid sequence of EpCAM-28-30S-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-CD28 ICD-CD30S ICD-CD3 zeta) 109 EpCAM-28-BB-z nucleotide Nucleotide sequence of EpCAM-28-BB-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 110 EpCAM-28-BB-zamino acid Amino acid sequence of EpCAM-28-BB-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 111 EpCAM-30S-BB-z nucleotide Nucleotide sequence of EpCAM-30S-BB-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 112 EpCAM-30S-BB-zamino acid Amino acid sequence of EpCAM-30S-BB-z CAR (hCD8a LS-EpCAM VL-(G4S)3 linker-EpCAM VH-CD28 Hinge-CD28 TM- RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 113 PD-1 LS nucleotide Human PD-1 derived signal sequence nucleotide sequence 114 PD-1 LS amino acid Human PD-1 derived signal sequence amino acid sequence 115 PD-1 ECD nucleotide Nucleotide sequence of the human PD-1-derived extracellular domain 116 PD-1 ECD amino acid Amino acid sequence of the human PD-1-derived extracellular domain 117 PD-1™ nucleotide 15 bp nucleotide sequence of human PD-1-derived transmembrane domain 118 PD-1™ amino acid Amino acid sequence 5aa of the human PD-1-derived transmembrane domain 119 PD-1-28-z nucleotide Nucleotide sequence of PD-1-28-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-CD28 ICD-CD3 zeta) 120 PD-1-28-z amino acid Amino acid sequence of PD-1-28-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-CD28 ICD-CD3 zeta) 121 PD-1-BB-z nucleotide Nucleotide sequence of PD-1-BB-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-4-1BB ICD-CD3 zeta) 122 PD-1-BB-z amino acid Amino acid sequence of PD-1-BB-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-4-1BB ICD-CD3 zeta) 123 PD-1-30S-z nucleotide Nucleotide sequence of PD-1-30S-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-RSK-CD30S ICD-CD3 zeta) 124 PD-1-30S-z amino acid Amino acid sequence of PD-1-30S-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-RSK-CD30S ICD-CD3 zeta) 125 PD-1-28TM nucleotide Nucleotide sequence of PD-1-28TM (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-RSK-AA) 126 PD-1-28™ amino acid Amino acid sequence of PD-1-28TM (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-RSK-AA) 127 PD-1-28-30S-z nucleotide Nucleotide sequence of PD-1-28-30S-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-CD28 ICD-CD30S ICD-CD3 zeta) 128 PD-1-28-30S-zamino acid Amino acid sequence of PD-1-28-30S-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-CD28 ICD-CD30S ICD-CD3 zeta) 129 PD-1-28-BB-z nucleotide Nucleotide sequence of PD-1-28-BB-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 130 PD-1-28-BB-zamino acid Amino acid sequence of PD-1-28-BB-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 131 PD-1-30S-BB-z nucleotide Nucleotide sequence of PD-1-30S-BB-z CAR (hPD-1 LS-hPD-1 LS-hPD1TM5aa-CD28 TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 132 PD-1-30S-BB-zamino acid Amino acid sequence of PD-1-30S-BB-z CAR (hPD-1 LS-hPD-1 LS- hPD1TM5aa-CD28 TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 133 MSLN(MOR) VH nucleotide Mesothelin single-strand variable-heavy-strand variable nucleotide sequence 134 MSLN(MOR) VHamino acid Mesothelin single-strand variable-heavy-strand variable amino acid sequence 135 MSLN(MOR) VL nucleotide Mesothelin single-chain fragment variable-light-chain variable nucleotide sequence 136 MSLN(MOR) VLamino acid amino acid sequence of mesothelin single-chain fragment variable-light-chain variable 137 hMSLN(MOR)-28-znucleotide Nucleotide sequence of hMSLN(MOR)-28-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28hinge-CD28TM-CD28 ICD-CD3 zeta) 138 hMSLN(MOR)-28-zamino acid Amino acid sequence of hMSLN(MOR)-28-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-CD28 ICD-CD3 zeta) 139 hMSLN(MOR)-BB-znucleotide Nucleotide sequence of hMSLN(MOR)-BB-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-4-1BB ICD-CD3 zeta) 140 hMSLN(MOR)-BB-zamino acid Amino acid sequence of hMSLN(MOR)-BB-z CAR(hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-4-1BB ICD-CD3 zeta) 141 hMSLN(MOR)-30S-znucleotide Nucleotide sequence of hMSLN(MOR)-30S-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-RSK-CD30S ICD-CD3 zeta) 142 hMSLN(MOR)-30S-zamino acid Amino acid sequence of hMSLN(MOR)-30S-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM- RSK-CD30S ICD-CD3 zeta) 143 hMSLN(MOR)-28-30S-znucleotide Nucleotide sequence of hMSLN(MOR)-28-30S-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-CD28 ICD-CD30S ICD-CD3 zeta) 144 hMSLN(MOR)-28-30S-z amino acid Amino acid sequence of hMSLN(MOR)-28-30S-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28hinge-CD28TM-CD28 ICD-CD30S ICD-CD3 zeta) 145 hMSLN(MOR)-28-BB-znucleotide Nucleotide sequence of hMSLN(MOR)-28-BB-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-CD28 ICD-4-1BB ICD-CD3 zeta) 146 hMSLN(MOR)-28-BB-zamino acid Amino acid sequence of hMSLN(MOR)-28-BB-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker-MSLN(MOR) VL-CD28 hinge-CD28TM-CD28 ICD-4-1BB ICD-CD3 zeta) 147 hMSLN(MOR)-30S-BB-znucleotide Nucleotide sequence of hMSLN(MOR)-30S-BB-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 148 hMSLN(MOR)-30S-BB-zamino acid Amino acid sequence of hMSLN(MOR)-30S-BB-z CAR (hGMCSF rec LS-MSLN(MOR) VH-(G4S)3 linker- MSLN(MOR) VL-CD28 hinge-CD28TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 149 NKp30 LS nucleotide Human NKp30-derived signal sequence (lead sequence) nucleotide sequence 150 NKp30 LS amino acid Human NKp30-derived signal sequence amino acid sequence 151 NKp30 ECD nucleotide Nucleotide sequence of the extracellular domain derived from human NKp30 152 NKp30 ECD amino acid Amino acid sequence of the human NKp30-derived extracellular domain 153 NKp30™ nucleotide 15 bp nucleotide sequence of human NKp30-derived transmembrane domain 154 NKp30™ amino acid Amino acid sequence 5aa of the human NKp30-derived transmembrane domain 155 NKp30-28-30S-z nucleotide Nucleotide sequence of NKp30-28-30S-z CAR (hNKp30 LS-hNKp30 ECD-hNKp30 TM 5aa-CD28TM-CD28 ICD-CD30S ICD-CD3 zeta) 156 NKp30-28-30S-z amino acid Amino acid sequence of NKp30-28-30S-z CAR (hNKp30 LS-hNKp30 ECD-hNKp30 TM 5aa-CD28TM-CD28 ICD-CD30S ICD-CD3 zeta) 157 NKp30-28-BB-z nucleotide Nucleotide sequence of NKp30-28-BB-z CAR (hNKp30 LS-hNKp30 ECD-hNKp30 TM 5aa-CD28TM-CD28 ICD-4-1BB ICD-CD3 zeta) 158 NKp30-28-BB-zamino acid Amino acid sequence of NKp30-28-BB-z CAR (hNKp30 LS-hNKp30 ECD-hNKp30 TM 5aa-CD28TM-CD28 ICD-4-1BB ICD-CD3 zeta) 159 NKp30-30S-BB-z nucleotide Nucleotide sequence of NKp30-30S-BB-z CAR (hNKp30 LS-hNKp30 ECD-hNKp30 TM 5aa-CD28TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 160 NKp30-30S-BB-zamino acid Amino acid sequence of NKp30-30S-BB-z CAR (hNKp30 LS-hNKp30 ECD-hNKp30 TM 5aa-CD28TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 161 Ig LS nucleotide nucleotide sequence of the signal sequence (lead sequence) derived from the human immunoglobulin heavy chain 162 Ig LS amino acid Amino acid sequence of a signal sequence derived from human immunoglobulin heavy chain 163 GPC3 VH nucleotide Glypican3 single-strand variable-heavy-strand variable nucleotide sequence 164 GPC3 VH amino acid Glypican3 single-strand fragment variable-heavy-strand variable amino acid sequence 165 GPC3 VL nucleotide Glypican3 single-strand fragment variable-light-strand variable nucleotide sequence 166 GPC3 VL amino acid Amino acid sequence of Glypican3 single-chain fragment variable-light-chain variable 167 GPC3-28-30S-znucleotide Nucleotide sequence of GPC3-28-30S-z CAR (immunoglobulin heavy-chain LS-Glypican3 VH-(G4S)3 linker- Glypican3 VL-AAA-CD28 hinge-CD28TM-CD28 ICD-CD30S ICD-CD3 zeta) 168 GPC3-28-30S-zamino acid Amino acid sequence of GPC3-28-30S-z CAR (immunoglobulin heavy-chain LS-Glypican3 VH-(G4S)3 linker- Glypican3 VL-AAA-CD28 hinge-CD28TM-CD28 ICD-CD30S ICD-CD3 zeta) 169 GPC3-28-BB-znucleotide Nucleotide sequence of GPC3-28-BB-z CAR (immunoglobulin heavy-chain LS-Glypican3 VH-(G4S)3 linker- Glypican3 VL-AAA-CD28 hinge-CD28TM-CD28 ICD-CD30S ICD-CD3 zeta) 170 GPC3-28-BB-zamino acid Amino acid sequence of GPC3-28-BB-z CAR (immunoglobulin heavy-chain LS -Glypican3 VH- (G4S)3 linker- Glypican3 VL-AAA-CD28 hinge-CD28TM-CD28 ICD-4-1BB ICD-CD3 zeta) 171 GPC3-30S-BB-znucleotide Nucleotide sequence of GPC3-30S-BB-z CAR (immunoglobulin heavy-chain LS -Glypican3 VH- (G4S)3 linker- Glypican3 VL-AAA-CD28 hinge-CD28TM-CD28 ICD-4-1BB ICD-CD3 zeta) 172 GPC3-30S-BB-zamino acid Amino acid sequence of GPC3-30S-BB-z CAR (immunoglobulin heavy-chain LS -Glypican3 VH- (G4S)3 linker- Glypican3 VL-AAA-CD28 hinge-CD28TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 173 BCMA VH nucleotide BCMA single-strand variable-heavy-strand variable nucleotide sequence 174 BCMA VH amino acid BCMA single-strand variable-heavy-strand variable amino acid sequence 175 BCMA VL nucleotide BCMA single-strand fragment variable-light-strand variable nucleotide sequence 176 BCMA VL amino acid BCMA single-chain fragment variable-light chain variable amino acid sequence 177 BCMA-28-30S-z nucleotide Nucleotide sequence of BCMA-28-30S-z CAR (hGMCSF rec LS-BCMA VH-(G4S)3 linker-BCMA VL-AAA-CD28 Hinge-CD28 TM-CD28 ICD-CD30S ICD-CD3 zeta) 178 BCMA-28-30S-z amino acid Amino acid sequence of BCMA-28-30S-z CAR (hGMCSF rec LS-BCMA VH-(G4S)3 linker-BCMA VL-AAA-CD28 Hinge-CD28 TM-CD28 ICD-CD30S ICD-CD3 zeta) 179 BCMA-28-BB-z nucleotide Nucleotide sequence of BCMA-28-BB-z CAR (hGMCSF rec LS-BCMA VH-(G4S)3 linker-BCMA VL-AAA-CD28 Hinge-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 180 BCMA-28-BB-z amino acid Amino acid sequence of BCMA-28-BB-z CAR (hGMCSF rec LS-BCMA VH-(G4S)3 linker-BCMA VL-AAA-CD28 Hinge-CD28 TM-CD28 ICD-4-1BB ICD-CD3 zeta) 181 BCMA-30S-BB-z nucleotide Nucleotide sequence of BCMA-30S-BB-z CAR (hGMCSF rec LS-BCMA VH-(G4S)3 linker-BCMA VL-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta) 182 BCMA-30S-BB-z amino acid Amino acid sequence of BCMA-30S-BB-z CAR (hGMCSF rec LS-BCMA VH-(G4S)3 linker-BCMA VL-AAA-CD28 Hinge-CD28 TM-RSK-CD30S ICD-4-1BB ICD-CD3 zeta)
[0166] (mRNA synthesis)
[0167] The above plasmid vector was amplified using the MN NucleoBond Xtra Midi Plus Endotoxin-free kit. The amplified plasmid vector was linearized using restriction enzymes. mRNA was produced via in vitro transcription using the linearized plasmid as a template. After performing the transcription process using the MEGAscript® Kit (AM1330, AMBION), the samples were treated with DNase, and the final mRNA was produced through 3' poly(A) tailing using the Poly(A) Tailing kit (AM1350, AMBION). After dispensing the mRNA at a rate of 40 µg / tube, the concentration and quality were verified using a nanodrop instrument and a tapestation. The mRNA products were stored at -80°C and used for CAR evaluation.
[0168] (Gene transfer (electroporation))
[0169] To introduce the CAR gene into KHYG-1 cells and NK-92 cells, 1×10 7 The cells were centrifuged at 1500 rpm for 3 minutes. After centrifugation, the cells were resuspended in 300 µl of opti-MEM culture medium. 40 µg of CAR mRNA was added to the cells, and electroporation was performed under conditions of 200 V, 2 ms, and 1 cycle. For alpha-beta T cells and gamma-delta T cells, 40 µg of mRNA was introduced into the same number of cells as above under conditions of 380 V, 1 ms, and 1 cycle.
[0170] (CAR expression detection)
[0171] To detect anti-CD19 CAR and anti-EpCAM CAR introduced into NK-92, KHYG-1, alpha-beta T cells, and gamma delta T cells, the samples were washed with 4% bovine serum albumin (BSA) buffer and stained for 30 minutes using Protein L or human Fab antibodies. After the reaction time was complete, the samples were washed with 4% BSA buffer and fixed with 2% PFA solution. The group stained with Protein L was stained for an additional 25 minutes using Streptavidin-PE antibody, followed by washing with 4% BSA buffer and fixation with 2% PFA solution. Anti-BCMA CAR, anti-MSLN CAR, and anti-GPC3 CAR were detected by staining with mouse Fab antibodies in the same manner as described above. Human anti-PD-1 antibodies were used for the detection of PD-1 CAR. Additionally, human anti-NKp30 antibodies were used for NKp30 CAR. The expression ratios of the stained cells were measured using the aurora (Cytek) instrument.
[0172] (Luciferease-based cytotoxicity)
[0173] Luciferase-gene-introduced target cells were placed in a 96-well plate at a volume of 50 µl in 1 x 10⁻⁶ 4 The cells were added to a cell / well. 50 µl of CAR gene-introduced effector cells were added at various E / T (effector-to-target) ratios and incubated in a 37°C incubator. After 4 hours of incubation, 100 µl of Bright-Glo solution was added, and the mixture was shaken at 500 rpm for 2 minutes. After incubation, the reaction solution was thoroughly mixed with a pipette, and 100 µl was transferred to a white, opaque 96-well plate. Fluorescence values were then measured at [wavelength] and [wavelength] using a microplate reader. Cytotoxicity was calculated as follows: percent specific lysis = 100-target with effector / only target x 100.
[0174] (Cytokine)
[0175] After irradiating target cells with 120 Gy X-rays, 1 x 10⁻¹⁰ cells were placed in a 96-well plate to a volume of 100 µL. 5 They were inserted in cells / well. To ensure an E / T ratio of 1, the CAR gene-introduced effector cells were also 1 x 10⁶ 5 The cells were placed in a cell / well. After incubating in a 37°C cell incubator for 24 hours, the plate was centrifuged at 1500 rpm for 5 minutes, and 150 µl of the supernatant was collected. The amount of secreted cytokines was measured according to the experimental method of the Human CD8 / NK Multi-Analyte Flow Assay Kit (BioLegend, SD, USA).
[0176] <Experimental Example 1> Evaluation of cytotoxicity of various immune cells expressing CARs using various forms of CD30 domains as co-stimulatory domains on CD19-negative and positive hematological cancer cell lines
[0177] To find the optimal CD30 domain as a co-stimulatory domain capable of enhancing the anti-tumor efficacy of immune cells, a second-generation CAR containing a CD30 domain targeting the human CD19 antigen was constructed using the plasmids of the above examples with the structures mentioned in Table 1 (Fig. 1a). The constructed second-generation CARs are as follows: CD19-30L-z (1219-1785 nt of the CD30 sequence), CD19-30M-z (1501-1785 nt of the CD30 sequence), and CD19-30M mut -z (change of lysine at amino acid 521 in CD30 sequence 1501-1785 nt to glutamine, 521 K→Q), CD19-30ΔM-z (deletion of Δ1615-1677 nt in CD30 sequence 1501-1785 nt, D1615-1677), CD19-30S-z (1615-1785 nt in CD30 sequence).
[0178] The above CAR mRNA was introduced into natural killer cell lines KHYG-1 and NK-92, as well as alpha-beta T cells and gamma-delta T cells, and its expression and anti-tumor efficacy in various immune cells were confirmed.
[0179] In all immune cells, CD19-28-z, CD19-30L-z, and CD19-30S-z were expressed at high levels, but CD19-30M-z, CD19-30M mut -z, CD19-30ΔM-z were hardly expressed (Fig. 1c).
[0180] In the evaluation of cytotoxic efficacy against CD19-negative and positive hematological cancer cell lines, only CD19-28-z and CD19-30S-z specifically killed CD19-positive cancer cell lines (Fig. 1d).
[0181] Therefore, the inventors selected CD30S as the optimal co-stimulation domain and conducted subsequent experiments.
[0182] <Experimental Example 2> Evaluation of cytotoxicity of various immune cells expressing CARs using a modified CD30S domain as a co-stimulatory domain on CD19-negative and positive hematological cancer cell lines
[0183] In the above experiment, among CAR structures containing various forms of CD30 domains, only the CAR structure containing CD30S was stably expressed in various immune cells and exhibited excellent antitumor efficacy. To facilitate the combination of third-generation CAR forms using the CD30S domain or with interleukin and chemokine receptors in the future, the inventors evaluated the antitumor efficacy after fabricating the CD30S domain into a smaller form, CD30ΔS. As shown in Figure 2a, mRNAs of CD19-28-z, CD19-30L-z, CD19-30S-z, and CD19-CD30ΔS-z (1630-1764 nt of CD30 sequence) were introduced into alpha-beta T cells and gamma-delta T cells via electroporation, and the cytotoxic efficacy against CD19-positive and negative cancer cell lines was evaluated.
[0184] CD19-28-z and CD19-30S-z were stably expressed in both alpha-beta T cells and gamma-delta T cells and exhibited high apoptotic activity. Although CD19-CD30ΔS-z was relatively lower in gamma-delta T cells compared to alpha-beta T cells, it effectively killed CD19-positive hematological malignancies in both cell types (Figs. 2b and 2c).
[0185] Next, to further enhance the function of the CD30ΔS domain, the phosphoinositide 3-kinase binding sites YMNM and YMFM, respectively present in the existing co-stimulatory domains CD28 and ICOS, were added to CD30ΔS, and the antitumor efficacy was evaluated. CD19-28-z, CD19-30S-z, CD19-CD30ΔS YN -z (linkage of CD30 sequence 1630–1764 nt and CD28 sequence 562–609 nt), CD19-CD30ΔS YF-z (a linkage of 1630-1764 nt of the CD30 sequence and 193 of the CD28 sequence, in which asparagine is changed to phenylalanine, N→F) mRNA was introduced into alpha-beta T cells and gamma-delta T cells.
[0186] CD19- CD30ΔS YN -z, CD19-CD30ΔS YF All -z CARs were stably expressed in alpha-beta T cells and gamma-delta T cells, and cytotoxic efficacy similar to that of T cells introduced with existing CD19-28-z and CD19-30S-z CARs was confirmed (Figs. 2d and 2e).
[0187] <Experimental Example 3> Comparison of cytotoxicity and cytokine secretion ability of alpha-beta T cells and gamma-delta T cells expressing CARs using CD30S or existing intracellular signaling domains as co-stimulatory domains against CD19-negative and positive hematological cancer cell lines
[0188] To determine whether alpha-beta T cells and gamma-delta T cells expressing CARs using CD30S or existing ICDs (CD28, 4-1BB, CD27, ICOS, OX40) as co-stimulatory domains specifically kill cancer cells, CD19-28-z, CD19-4-1BB-z, CD19-27-z, CD19-ICOS-z, CD19-OX40-z, and CD19-30S-z CAR mRNAs were introduced into alpha-beta T cells and gamma-delta T cells via electroporation (Fig. 3a).
[0189] The remaining CARs, excluding CD19-ICOS-z and CD19-OX40-z, were stably expressed in alpha-beta T cells and gamma-delta T cells. CD19-positive cancer cell line U937 CD19Against IM-9 and Raji, both alpha-beta T cells and gamma-delta T cells expressing CD19-30S-z CARs were confirmed to exhibit cytotoxic efficacy similar to that of cells expressing CARs containing existing ICDs. On the other hand, the aforementioned CARs [were used] against the CD19-negative cell line U937 mock For this group, almost no cytotoxic activity was exhibited, similar to the group without the CAR gene introduced (NT) (Figs. 3b to 3d).
[0190] In addition, alpha-beta T cells and gamma-delta T cells expressing the above-mentioned anti-CD19 second-generation CAR were respectively CD19-positive U937 CD19 and voice U937 mock The amounts of secreted cytokines IFN-γ, TNF-α, granzyme A, granzyme B, and perforin were measured after incubation with.
[0191] In alpha-beta T cells, CD19-30S-z CAR secreted the aforementioned cytokines in smaller amounts than CD19-28-z and in amounts similar to CD19-4-1BB-z. On the other hand, in gamma delta T cells against CD19-positive cell lines, CD19-30S-z CAR secreted amounts of IFN-γ and TNF-α that were smaller than CD19-28-z but larger than CD19-4-1BB-z. CD19-30S-z secreted granzyme A, granzyme B, and perforin to a degree similar to that of CD19-28-z (Fig. 3e).
[0192] <Experimental Example 4> Comparison of cytotoxicity and cytokine secretion ability of alpha-beta T cells and gamma-delta T cells expressing a third-generation CAR using CD30S as a co-stimulatory domain against CD19-negative and positive hematological cancer cell lines
[0193] To determine whether alpha-beta T cells and gamma-delta T cells expressing a third-generation CAR, in which one of the two co-stimulation domains uses CD30S as a co-stimulation domain and the other uses the existing ICD (CD28, 4-1BB, CD27, ICOS, OX40) as a co-stimulation domain, react antigen-specifically, CD19-28-BB-z, CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-27-z, CD19-30S-ICOS-z, and CD19-30S-OX40-z mRNAs were constructed with the structures mentioned in the plasmid of the example above (Fig. 4a).
[0194] The above anti-CD19 3rd generation CAR mRNA was introduced into alpha-beta T cells and gamma-delta T cells using electroporation, and all CARs were stably expressed in alpha-beta T cells and gamma-delta T cells (Fig. 4b).
[0195] In addition, CARs using CD30S as a co-stimulatory domain (CD19-30S-BB-z, CD19-28-30S-z, CD19-30S-27-z, CD19-30S-ICOS-z, CD19-30S-OX40-z) similarly to the existing CD19-28-BB-z in the CD19-positive cell line U937 CD19 Specific cytotoxic activity against IM-9 and Raji was confirmed. On the other hand, CD19-negative cell line U937 mock It did not show cytotoxic activity against (Fig. 4c).
[0196] In addition, alpha-beta T cells and gamma-delta T cells expressing CD19-28-BB-z, CD19-30S-BB-z, and CD19-28-30S-z CARs were U937 mock , U937 CD19 The amount of secreted cytokines was measured after incubation with.
[0197] CD19-positive U937 in both alpha-beta T cells and gamma-delta T cells CD19Regarding this, CD19-30S-BB-z and CD19-28-30S-z CARs using CD30S as an auxiliary stimulation domain secreted larger amounts of IFN-γ, TNF-α, granzyme A, and granzyme B than CD19-28-BB-z (Fig. 4d).
[0198] <Experimental Example 5> Evaluation of cytotoxicity of gamma delta T cells expressing a CAR targeting human BCMA antigen using CD30S as a co-stimulatory domain against human hematological cancer cell lines
[0199] To evaluate the efficacy of the CD30S co-stimulatory domain in a CAR targeting BCMA expressed in human hematological malignancies, BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above examples (Fig. 5a). In addition, human BCMA expression was measured in human hematological malignancy cell lines U937, IM-9, and Daudi. BCMA was not expressed in U937, while it was expressed in IM-9 and Daudi (Fig. 5b).
[0200] BCMA-28-BB-z, BCMA-30S-BB-z, and BCMA-28-30S-z mRNA were introduced into gamma delta T cells, respectively, using electroporation. BCMA-30S-BB-z and BCMA-28-30S-z containing CD30S were stably expressed in gamma delta T cells, while BCMA-28-BB-z was expressed at a very low level (Fig. 5c). Gamma delta T cells expressing BCMA-30S-BB-z and BCMA-28-30S-z exhibited high cytotoxic activity against BCMA-positive cell lines IM-9 and Daudi, but showed no cytotoxic activity against BCMA-negative cell line U937 (Fig. 5d).
[0201] <Experimental Example 6> Evaluation of cytotoxicity of alpha-beta T cells and gamma-delta T cells expressing a CAR targeting a human EpCAM antigen using CD30S as a co-stimulatory domain on human solid tumor cell lines
[0202] To evaluate the efficacy of the CD30S co-stimulation domain in CARs targeting EpCAM expressed in human solid tumors, EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z, and EpCAM-28TM mRNAs were synthesized with the structures mentioned in the plasmids of the above examples. In addition, human EpCAM expression was measured in human lung cancer cell lines A549, Calu-1, NCI-H292, and NCI-H460. EpCAM was expressed at a rate of over 70% in lung cancer cell lines A549, Calu-1, NCI-H292, and NCI-H460. EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z, and EpCAM-28TM mRNAs were introduced into alpha-beta T cells and gamma-delta T cells, respectively, using electroporation (Fig. 6a).
[0203] EpCAM-28-z, EpCAM-4-1BB-z, EpCAM-30S-z, and EpCAM-28TM chimeric antigen receptors were all highly expressed in alpha-beta T cells and gamma-delta T cells (Fig. 6B). Alpha-beta T cells and gamma-delta T cells expressing EpCAM-28-z, EpCAM-4-1BB-z, and EpCAM-30S-z were evaluated to have similar cytotoxic activity against lung cancer cell lines expressing EpCAM, whereas the group without CAR introduction (NT) and the group with EpCAM-28TM introduction did not show cytotoxic activity (Figs. 6C and 6D).
[0204] In addition, to evaluate the efficacy of the CD30S co-stimulatory domain in a third-generation CAR targeting EpCAM, EpCAM-28-BB-z, EpCAM-30S-BB-z, and EpCAM-28-30S-z mRNAs were synthesized with the plasmid structures mentioned in the above examples and introduced into alpha-beta T cells and gamma-delta T cells, respectively (Fig. 6e).
[0205] EpCAM-28-BB-z, EpCAM-30S-BB-z, and EpCAM-28-30S-z were all stably expressed in alpha-beta T cells and gamma-delta T cells (Fig. 6f). Alpha-beta T cells introduced with the aforementioned EpCAM 3rd generation CARs were evaluated to have excellent cytotoxic efficacy against A549, Calu-1, NCI-H292, and NCI-H460. In gamma-delta T cells as well, the EpCAM CARs effectively killed EpCAM-positive lung cancer cell lines (Fig. 6g).
[0206] <Experimental Example 7> Evaluation of cytotoxicity of alpha-beta T cells and gamma-delta T cells expressing a CAR targeting human mesothelin antigen using CD30S as a co-stimulatory domain on human solid tumor cell lines
[0207] To evaluate the efficacy of the CD30S co-stimulatory domain in CARs targeting mesothelin expressed in human solid tumors, human mesothelin expression was measured in human lung cancer cell lines A549 and NCI-H292, human pancreatic cancer cell line AsPC-1, and human ovarian cancer cell line SKOV3. Mesothelin was highly expressed in lung cancer cell line NCI-H292 and pancreatic cancer cell line AsPC-1, and low in lung cancer cell line A549 and ovarian cancer cell line SKOV3 (Fig. 7b). MSLN-28-z, MSLN-4-1BB-z, and MSLN-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above example and introduced into alpha-beta T cells and gamma-delta T cells, respectively (Fig. 7a).
[0208] The above-mentioned anti-mesothelin second-generation CARs were expressed at high levels in alpha-beta T cells and gamma-delta T cells (Fig. 7c). Cytotoxic efficacy was confirmed in alpha-beta T cells and gamma-delta T cells introduced with MSLN-28-z and MSLN-4-1BB-z CARs only against mesothelin-positive NCI-H292 and AsPC-1. Alpha-beta T cells and gamma-delta T cells introduced with MSLN-30S-z CARs showed slightly lower cytotoxic efficacy than MSLN-28-z and MSLN-4-1BB-z CARs. It was confirmed that MSLN-28-z, MSLN-4-1BB-z, and MSLN-30S-z CARs all exhibited cytotoxic efficacy specifically only in cell lines expressing mesothelin (Fig. 7d).
[0209] In addition, to evaluate the efficacy of the CD30S co-stimulatory domain in third-generation CARs targeting mesothelin, MSLN-28-BB-z, MSLN-30S-BB-z, and MSLN-28-30S-z mRNAs were synthesized with the structure mentioned in the plasmid of the example above and introduced into alpha-beta T cells and gamma-delta T cells, respectively, using electroporation (Fig. 7e). All MSLN-28-BB-z, MSLN-30S-BB-z, and MSLN-28-30S-z CARs were highly expressed in alpha-beta T cells and gamma-delta T cells (Fig. 7f). In the case of the remaining MSLN-CAR alpha-beta T cells excluding the NT group, cytotoxic activity was shown only against NCI-H292, and no cytotoxic activity was shown against AsPC-1, SKOV3, and A549. In gamma delta T cells, the above anti-mesothelin 3rd generation CARs selectively killed only NCI-H292 and AsPC-1, which highly express mesothelin (Fig. 7g).
[0210] <Experimental Example 8> Evaluation of cytotoxicity of gamma delta T cells expressing a CAR targeting human GPC3 antigen using CD30S as a co-stimulatory domain on human solid tumor cell lines
[0211] To evaluate the efficacy of the CD30S co-stimulatory domain in a CAR targeting GPC3 expressed in human solid tumors, GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above examples (Fig. 8a). Human GPC3 expression was measured in human liver cancer cell line HepG2 and human lung cancer cell lines NCI-H292 and A549. GPC3 was expressed in liver cancer cell line HepG2, but not in lung cancer cell lines NCI-H292 and A549 (Fig. 8b).
[0212] GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z mRNA were introduced into gamma delta T cells, respectively, using electroporation. GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z CARs were all stably expressed in gamma delta T cells (Fig. 8c). Gamma delta T cells expressing GPC3-28-BB-z, GPC3-30S-BB-z, and GPC3-28-30S-z CARs showed specific cytotoxic activity only against the GPC3-positive cell line HepG2, but did not exhibit cytotoxic activity against the negative cell lines NCI-H292 and A549 (Fig. 8d).
[0213] <Experimental Example 9> Evaluation of cytotoxicity of alpha-beta T cells and gamma-delta T cells expressing a CAR targeting human PD-L1 antigen using CD30S as a co-stimulatory domain on human solid tumor cell lines
[0214] To evaluate the efficacy of the CD30S co-stimulation domain in CARs targeting PD-L1 expressed in human solid tumors, PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM mRNAs were synthesized using the plasmid structures mentioned in the above examples (Fig. 9a). Human PD-L1 expression was measured in lung cancer cell lines NCI-H292 and Calu-1, pancreatic cancer cell line AsPC-1, and head and neck cancer cell line FaDu. PD-L1 was highly expressed in all cell lines (Fig. 9b). PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM mRNAs were introduced into alpha-beta T cells and gamma-delta T cells, respectively, using electroporation. PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z, and PD-1-28TM CARs were all highly expressed in alpha-beta T cells and gamma-delta T cells (Fig. 9c). In the case of alpha-beta T cells, CARs other than NT and PD-1-28TM CAR T cells exhibited cytotoxic activity only against NCI-H292 and Calu-1. On the other hand, in gamma-delta T cells, the aforementioned CARs (PD-1-28-z, PD-1-4-1BB-z, PD-1-30S-z) selectively killed NCI-H292, Calu-1, and FaDu. None of the PD-1 CARs exhibited cytotoxic activity against the PD-L1-positive cell line AsPC-1 (Fig. 9d).
[0215] In addition, to evaluate the efficacy of the CD30S co-stimulatory domain in third-generation CARs targeting PD-L1, PD-1-28-BB-z, PD-1-30S-BB-z, and PD-1-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above examples and introduced into gamma delta T cells, respectively, using electroporation (Fig. 9e). PD-1-28-BB-z, PD-1-30S-BB-z, and PD-1-28-30S-z CARs were all highly expressed in gamma delta T cells (Fig. 9f). Similar to the results of cytotoxicity experiments on gamma delta T cells introduced with PD-1 second-generation CARs, gamma delta T cells introduced with the PD-1 third-generation CARs selectively killed NCI-H292, Calu-1, and FaDu, but did not show killing ability against AsPC-1 (Fig. 9g).
[0216] <Experimental Example 10> Evaluation of cytotoxicity of alpha-beta T cells and gamma-delta T cells expressing a CAR targeting human B7-H6 antigen using CD30S as a co-stimulatory domain on human solid tumor cell lines
[0217] To evaluate the efficacy of the CD30S co-stimulatory domain in a CAR targeting B7-H6 expressed in human solid tumors, NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z mRNAs were synthesized using the plasmid structures mentioned in the above example (Fig. 10a). Human B7-H6 expression was measured in human lymphoma cell lines U937 and K562, human Burkitt lymphoma cell line Raji, and human lung cancer cell lines. B7-H6 was not expressed in A549, while B7-H6 was expressed by more than 70% in U937, Raji, and K562 (Fig. 10b).
[0218] NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z mRNA were introduced into alpha-beta T cells and gamma-delta T cells, respectively, using electroporation. NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z CARs were all stably expressed in alpha-beta T cells and gamma-delta T cells (Fig. 10c). Alpha-beta T cells and gamma-delta T cells expressing NKp30-28-BB-z, NKp30-30S-BB-z, and NKp30-28-30S-z CARs were confirmed to have specific cytotoxic activity against B7-H6 positive cell lines U937, Raji, and K562, but did not show cytotoxic activity against negative cell line A549 (Fig. 10d).
[0219] <Experimental Example 11> Therapeutic antitumor effect of 2nd generation CD19-CAR expressing T cells according to the combination of CD30S and conventional ICD (CD28, 4-1BB) in an animal model xenografted with human leukemia cell line NALM6
[0220] The evaluation and experimental methods for the antitumor activity of second-generation CD19-CAR-expressing T cells are as follows.
[0221] (Mouse, cell line)
[0222] Six-week-old female NOG (NOD.Cg-Prkdc scid Il2rg tm1sug / JicKoat) mice were purchased from Koatech Inc. (Pyeongtaek, Kyunggi) and housed under sterile conditions in the animal laboratory of the Catholic University of Korea. All procedures of the animal study were conducted in accordance with the guidelines and policies on rodent experiments provided by the Institutional Animal Care and Use Committee (IACUC) of the College of Medicine, Catholic University of Seoul (Approval number: CUMS-2022-0285-02), the guide on the care and use of laboratory animals, and the Laboratory Animal Welfare Act. NALM6 cells were purchased from the American Type Culture Collection (Manassas, VA), and all cell lines were cultured according to the manufacturer's recommendations.
[0223] (Evaluation of therapeutic antitumor effects)
[0224] To evaluate the therapeutic effect in vivo, 1x10 6 1 x 10⁶ NALM-6-luc-thy1.1 cells on day 7 after intravenous administration 7 CD19-CAR-αβ T cells were administered once intravenously. Mice that did not receive cell therapy (No Treat) were included as a control group. Tumor growth was monitored in individual mice over time using in vivo bioluminescence imaging, and animal body weight was measured at fixed time points; mice that showed a weight loss of more than 20% were euthanized according to the approved animal protocol.
[0225] Tumor growth over time was monitored by detecting bioluminescence in whole animals using IVIS Lumina XRMS (in vivo luminescence imaging). Luciferin (Promega, P1043) was prepared at a concentration of 15 mg / mL using sterile physiological saline and stored in a -80°C freezer, thawed to 37°C before use. To confirm bioluminescence, mice were injected intraperitoneally with 3 mg / 200 µL of luciferin and waited for a reaction time of 7–8 minutes. After the reaction time ended, mice were kept under anesthesia throughout the entire imaging process via a nose cone isofluorane oxygen delivery system while bioluminescence was measured in a light-leakage chamber. Tumor growth image analysis was evaluated by quantifying the average in vivo bioluminescence intensity in individual mice.
[0226] As shown in Figures 11a-b, an animal model was established in which human leukemia cell line NALM6 was xenografted to evaluate the in vivo efficacy of αβ T-cell therapies transduced with CD30S targeting CD19 or second-generation CARs using existing co-stimulatory domains. The results showed that the antitumor effects of CD19-28-z, CD19-4-1BB-z, and CD19-30S-z CAR-αβ T-cells exhibited therapeutic benefits, such as delayed tumor growth and increased viability, compared to untransduced αβ T-cell therapies. Among them, the CD19-30S-z CAR-αβ T-cell therapy group had substantially higher antitumor effects than the CD19-28-z, CD19-4-1BB-z, and CAR-αβ T-cell therapy groups, and no significant toxicity was observed.
Claims
Claim 1 A chimeric antigen receptor comprising a target antigen binding domain; a transmembrane domain; an intracellular signaling domain consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO: 44, 46, 48 and 50; and a CD3ζ intracellular signaling domain. Claim 2 In claim 1, the target antigen binding domain comprises a chimeric antigen receptor comprising an antibody or a fragment thereof that specifically binds to a target antigen. Claim 3 In claim 1, the target antigen is CD19, MUC16, MUC1, CAIX, CEA, CDS, CD7, CD10, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, BCMA, PD-1, NKp30, cytomegalovirus (CMV) infected cell antigen, EGP-2, EGP-40, EpCAM, Erb-B2, Erb-B3, Erb-B4, FBP, fetal acetylcholine receptor, folate receptor-α, GD2, GD3, HER-2, hTERT, IL-13R-α2, κ-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, NKG2D ligand, NY-ESO-1, carcinoembryo Chimeric antigen receptor selected from the group consisting of antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, CD24, CD47, EGFR, CD123, GPC3, CD117, Claudin18.2, cMET, EphA2, CLL-1, CD171, AXL, ROR2, FAP, and CD5. Claim 4 A chimeric antigen receptor according to claim 1, wherein the transmembrane domain is a transmembrane domain of any molecule selected from the group consisting of CD8, 4-1BB (CD137), CD27, CD28, CD30, 0X40 (CD134), CD3e, CD3ζ, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD154 and ICOS (CD278) or a transmembrane domain derived from said transmembrane domain. Claim 5 The chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor further comprises a hinge region between the C-terminus of the target antigen binding domain and the N-terminus of the transmembrane domain. Claim 6 The chimeric antigen receptor of claim 1 further comprises an intracellular signaling domain of any one molecule selected from the group consisting of CD27, CD28, 4-1BB(CD137), 0X40, CD40, ICOS, LFA-1 (lymphocyte function-associated antigen-1), CD2, CD7, NKG2C, CD83, Dap10, GITR, OX40L, Myd88-CD40, and KIR2DS2. Claim 7 The chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor further comprises a signal peptide at the N-terminus of a target antigen binding domain, said signal peptide is selected from the group consisting of a GM-CSF receptor signal sequence, a CD8α signal sequence, an immunoglobulin heavy chain signal sequence, a PD-1 signal sequence, and an NKp30 signal sequence. Claim 8 A nucleic acid molecule encoding the chimeric antigen receptor of claim 1. Claim 9 A vector containing the nucleic acid molecule of claim 8. Claim 10 Isolated recombinant immune effector cells comprising the chimeric antigen receptor of claim 1, the nucleic acid molecule of claim 8, or the vector of claim 9. Claim 11 In paragraph 10, the immune effector cells are isolated recombinant immune effector cells that are αβ T cells, γδ T cells, NK cells, NK T cells, or macrophages. Claim 12 An antitumor composition comprising isolated recombinant immune effector cells of claim 10.
Citation Information
Patent Citations
Single- and multi-chain chimeric antigen receptors
US20190194617A1
Chimeric antigen receptor t cells and uses thereof
WO2021016606A1
